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Though NMR has many applications in analytical chemistry, it 
has not been widely used for quantitative analysis. This has been 
due partly to high instrumental cost and relatively poor sensitivity. 
With advances in instrumentation and the development of new techniques, 
the full potential of" nmr for quantitative studies is now being 
investigated.
The use of nmr for quantitative analysis has been reviewed with 
particular reference to pharmaceuticals. The basis of the nmr quanti­
tative analysis and the factors affecting the suitability of the 
technique have been outlined. The theory and application of 
lanthanide shift reagents have been considered with emphasis on 
optical purity determination.
Chiral lanthanide shift reagents have been used successfully to 
determine enantiomeric ratio of many optically active compounds.
Three methods, namely, the base line technique, chemical shift diff­
erence and peak height difference methods have been developed to 
overcome the problem of accurate measurement of broad resonance 
peaks normally associated with the use of lanthanide shift reagents.
The application of the base line technique has been extended to non- 
enantiomeric compounds.
Modification of structures of some compounds is sometimes nece- 
sarry before the application of lanthanide shift reagents. An account 
of compounds which need modification has been given.
-IV-
The increasing number and complexity of pharmaceutical prepara­
tions encounted in routine analysis of drugs requires the application 
of techniques that are rapid, specific and accurate. In this thesis 
nmr as a quantitative tool for pharmaceuticals is fully investigated. 
Many pharmaceuticals of different.', dosage forms have been assayed 
successfully by the use of nmr.
A colorimetric method has been used for the kinetic studies of 
'Benoral' suspension, a preparation containing benorylate (4-acetamido- 
phenyl 2-acetoxybenzoate) . The suspension has been found to be quite:, 
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1. PART I - INTRODUCTION
— 1-
Advances in both instrumentation and application of nuclear
magnetic resonance (nmr) have arisen with remarkable speed following
the discovery of chemical shifts in 1951^ which set the stage for
the use of nmr as a probe into the structure of molecules. Before
this discovery, nmr was the domain of the physicist and was used
largely for the elucidation of fundamental nuclear phenomena and
the accurate determination of nuclear magnetic moments. The impact
of the technique on analytical chemistry is evidenced by the number
of chemical articles that have appeared in the literature over the
past few decades. Many of these are based on the application of
nmr to structure elucidation of new compounds. It is probably the
most powerful tool available for structure elucidation. Two of the
recent advances on the applications of nmr are the use of nmr for
2quantitative analysis of pharmaceuticals and, more recently, the
discovery of Lanthanide shift reagents which often simplify spectra^
4and allow optical purity determinations .
1.1 Quantitative Pharmaceutical Analysis
Nuclear magnetic resonance is a technique particularly suited
to quantitative measurements but the pharmaceutical applications were
not appreciated until 1963 when Hollis successfully analysed Aspirin,
2Phenacetin and Caffeine mixtures (APC) by nmr spectroscopy .
The application of nmr in quantitative analysis depends on the 
fact that the area beneath a particular nmr signal is directly pro­
portional to the number of protons frcm which the signal is derived 
so that the area under a Cîî̂  signal is thrice larger than that under 
a CH signal of the same molecule. The area (A) under a signal is
— 2—
given by
WA = K -   (1:1)
Where 'W' is the weight of the sample
'E ' is the equivalent weight of the compound which is given by
g _ Molecular weight of the compound________
the number of protons giving that signal
and 'K' is a constant.
Application of equation (1) in quantitative analysis requires at 
least two signals, one from the test sample and the other from a 
standard sample (see page 5 for an account of the standards
employed). The area (Â ) under the analytical signal for the test 
sample is given by
"tA = K—   (1:2)T
Similarly for the standard signal, the area (A ) is given by
” sA — K ——  ....(1:3)
Dividing equation (1:2) by equation (1:3) gives the weight of the 
test sample (Ŵ ) as
V t”s
«T = T i -  ....(1:4)
s s
Both peak height and area measurements are used in quantitative 
nmr analysis but it is the latter technique which is most often used, 
because it is only under certain conditions that peak heights are 
proportional to the number of protons giving rise to the signal, 
namely if the line widths are identical^. The peak height of the 
absorption mode of the nmr signal under slow passage conditions is 
given by
Y H j^N
 ̂ ~t (1+(YH )^T^T  (1:5)
-3-
where 'N ' is the number of nuclei and 't ' the absolute temperature. 
The dependence of the peak height on T^, which is a measure of the 
line width, and on the effects of spin-spin coupling, limits its 
usefulness in quantitative work. The area of the signal under the 
same conditions is given by
K'yH N
A = — ---   r----   (1:6)
(1+(YH^) T^T^
2For sufficiently low levels, (yH^) T^T^ <<1 and the area is 
approximately given by
K'yH N
A = — ------ (1:7)
In this case the relative areas of the signals in a spectrum are 
directly proportional to the numbers of nuclei giving rise to them. 
Peak heights are, however, preferred to area measurement of signals 
from very dilute solutions^, and also in the case of measurement in 
the proximity of other signals from the sample matrix or solvent^.
There are several ways of measuring the area under a signal but
the most commonly employed method is by integration using electronic
integrators which are available for most nmr spectrometers. The
height of the step of the integral curve (Î ) is proportional to
the area (A) under the peak.
I = KA  (1:8)T
where 'K' is a constant which depends on the sweep rate (R). Thus,
I^ = I   (1:9)
Other methods of area measurements include triangulation, cutting and 
weighing^, and by means of a planimeter^.
_4—
The accuracy of area measurement and the degree to which an area 
truly represents the number of protons giving rise to the integrated 
signal depends critically upon the following instrumental operating 
conditions :
(a) the signal-to-noise ratio, which must be high to avoid background 
noise contribution to the integration trace;
(b) a non-saturating mode of operation by a proper choice of radio­
frequency (rf) power level (H) and sweep rate (dH/dt); (At high 
levels a significant degree of saturation occurs, and since the 
relaxation times are not equal for all signals there is no longer a 
simple relationship between signal areas and numbers of nuclei. Both 
slow and rapid sweep rates are unsuitable for normal quantitative 
work. Sweep times for slow passage are unacceptably long, especially 
when measurements have to be repeated. On the other hand, sweep 
rates for rapid passage lead to considerable broadening, and cannot
be used for measurements of signals which are close together. 
Intermediate sweep rates are therefore used, and conditions have to 
be selected such that relaxation times do not affect relative peak 
areas );
(c) reduction of spinning side bands by careful adjustment of magnetic 
field homogeneity and use of high precision sample, tubes spinning 
at optimum rate;
(d) correct settings of both base line zero and tf phase control to 
give true absorption mode of operation and to avoid drifting or 
slope in the integral curves.
To minimise errors due to integration, analytical resonance signals
-5-
must be integrated several times (normally five times) and the 
average taken.
The use of an internal standard is a common practice in nmr 
quantitative analysis. The choice of internal standard is critical 
and depends upon several factors, including solubility and compati­
bility^' The standard and the test analytical peaks should not
coincide, and also the two peaks should have comparable areas to 
minimise errors caused by non-linearity of the electronic measuring 
circuits^. The material should be readily available^^ and should
give a single sharp resonance^' (this condition is not always met)
12Among the most common compounds used as standards are; 1,4-dioxan ,
11 10 tetramethyl ammonium bromide , biphenyl-or benzyl benzoate ,
hexamethylcyclotrisiloxane^^succinamide, t-butanol}^, maleic 
acid^^, malonic acid^, methanol^,fumaric acid^, maleic anhydride^, 
and cyclohexane^. Solvent satellites and residual protons
in deuterated solvents have also been used as internal standards^.
Though solvents used in nmr spectroscopy should be devoid 
of protons; this is not always possible and other proton-containing 
solvents have been used. The essential requirement is that the 
solvent should have a transparent spectrum in the analytical region 
and, in addition, the sample and standard must show acceptable 
solubility and compatibility with the solvent. For ordinary quan­
titative analysis, solvents commonly used include carbon tetra­
chloride, deuterated chloroform, tetrachloroethylene, carbon di­
sulphide, deuterated water, deuterated acetic acid and trifluoro- 
acetic acid^^' . Combinations of solvents can be used. For
-6-
example, in the analysis of methenamine and methenamine mandelate 
tablets, a mixture of formamide, acetone and acetonitrile (10 + 25 + 
65) was used as the solvent^^. The solvent system was selected to 
resolve problems of solubility of methenamine and its salt-methe- 
namine mandelate, overlapping of the resonance signals of the com­
ponents and potential decomposition of methanamine.
To overcome solubility and incompatibility problems, the
standard can be placed in a separate tube as an external standard.
An analytical technique for the determination of a molecular species
in a mixture employing an external standard in a precision coaxial
19tube has been developed . The method has also been used for 
the elemental determination of hydrogen, and for some binary 
mixtures by the measurement of chemical shift differences.
Since Hollis' Aspirin, Phenacetin and Caffeine (APC) mixtures
analysis in 1963, several reports of successful nmr analysis of
5-57pharmaceuticals have been published . In 1964 nmr spectroscopy 
was used for the characterization and quantification of detergent 
chemicals^^. For alkylbenzenes, alkylphenols, and ethylene oxide 
(EO) adducts of alkylphenols, the following quantities can be 
measured: average lengths of the alkyl chains, average molecular
weights, degree and kind of branching in the alkyl chain, ortho- 
para distribution of aryl substituents, and average lengths of EO 
chains. The procedure is simple. It involves integration of two 
major resonance bands in the nmr spectrum belonging to the aromatic 
protons (lower field) and the protons of the alkyl chain (higher 
field). Since the lower band results from exactly five protons
“7 —
(in the case of alkylbenzenes) per molecule, assuming only mono- 
alkylation, the average number of hydrogens in the alkyl chain, 
the average carbon number of the alkyl chain, as well as the average 
molecular weight of the sample can be readily obtained from the rel­
ative integrals of the two bands. Accuracy is of the order of ±2%
of the total hydrogen. A combination of nmr and mass spectrometry
21has been used to examine the purity of some non ionic surfactants
The importance of silicones in the pharmaceutical, cosmetic 
and food industries has given rise to various chemical and physical 
methods for the identification and quantitation of this material.
A simple nmr assay method for dimethyIpolysiloxane (dimethicone)
12coating in needles of syringes has been presented by Anhoury et al.
This involves the use of tetrachloroethylene as the solvent and
1,4-dioxane as the internal standard. The silicone on metal needles
cut from syringes is extracted with a mixture of tetrachloroethylene
and 1,4-dioxan (99.6:0.4, v/v) and the nmr spectra obtained on 0.5 ml
samples of the solution. The 1,4-dioxan signal at 63.54 ppm and the
silicone Q  3  signal at 60.1 ppm are used as the basis
for the analysis. This nmr method compares favourably with the
usual IR method which depends on analysis of the absorbance peak at 
—  11090 cm
Although a number of methods exist for the determination of hydroxyl
groups in simple mixtures and petroleum oils, a more reliable and
independent method is still needed to correlate the total hydroxyl
content and the nature of the hydroxyl moiety. Recently, an nmr
22method has been described by Schweighardt et al. for the character­
-8-
ization and quantitation of hydroxyl groups in complex organic mix­
tures by formation of their trimethyl silyl (TMS) derivatives. A 
series of model compounds was used to demonstrate the ninefold 
enhancement in proton nmr sensitivity, which subsequently gave 
a calculated hydroxyl content with an average error of 5%. This 
study also showed the chemical shift of the trimethylsilyl group 
protons in each TMS derivative formed to vary, in general, with the 
nature of the hydroxyl group - alcohols and benzylic hydroxyls 
being the most shielded and polynuclear aromatic carboxylic acids 
and oximes least. The method was then applied to the character­
ization of hydroxyl groups found in coal liquefaction oils and asph-
altenes. The use of TMS ether derivatives in nmr quantitation is
23 24also reported for fatty acids and hydroxyl in coal
To determine quantitatively the relative isomeric ratios of
113 (1:1A)- and 2^(1:IB)-Tetrazole-l-acetic acids and their ester
analogues, it was necessary to use a specific method. A fast and
25accurate nmr method has been described by Staiger et ai. . The 
method takes advantage of the significant difference in chemical 
shift of the methylene groups or the ring protons in the 1- and 2- 
tetrazole acetic acid and analogues. The relative ratio of the 
isomers is
  N-CHjCOOR C =  NI IN N N N-CHjCOOR
(1:1A) (1:1B)
_g_
determined from the measured intensities of the methylene groups.
The importance of this analysis is that the presence of the 2-isomer 
can lower the purity of the desired pharmacologically active material.
27 153The official ' assay procedure for synthetic corticosteroids
of the 1,4-dien-3-one type (1:2A) is by colourimetric methods based
173on the reduction of certain tétrazolium derivatives by the ^-ketol 







not distinguish between l,4-dien-3-ones and related corticosteroids
of the 4-en-3-one (1:2B) type, which may be present as impurities.
NMR spectroscopy affords a method of distinguishing easily between
the two groups of steroids. l,4-Dien-3-ones possess three vinylic
protons of which the chemical shift usually differs from that of the
single vinylic proton of 4-en-3-ones. It is, therefore, possible to
detect the two groups of compounds in the presence of each other,
and hence to develop a much more specific assay procedure. Avdovich 
28et al. have described an nmr method for the analysis of synthetic
corticosteroids of the l,4-dien-3-one type. Dimethyl sulphoxide
and fumaric acid were employed as the solvent and the internal standard
-10-
respectively. Both bulk drugs and formulations were assayed using
this method. Comparisons were made with results obtained from 
official assays on the steroids and their formulations. The
average deviation obtained with the nmr method was 0.5%. A pro­
cedure for the water-soluble 1,4-dien-3-ones (such as Prednisolone 
sodium phosphate (P.S.P)) was also described using triethylamine 
hydrochloride and D^O as the internal standard and solvent resp­
ectively. The signals at 7.586 (for PSP) and 3.226 (for triethyl­
amine hydrochloride) were used in the analysis.
An nmr assay procedure has also been developed for Mestranol 
29(1:3) . The method is based upon measurement of the nmr signals





acid as an internal standard and pyridine as the solvent.
NMR quantitative analysis has generally been accomplished with
the use of an internal standard. However, free thiadiazole (1:5)
in cefazolin (1:4) has been quantified by nmr spectroscopy using
a calibration curve derived from spectral data on known mixtures
prepared from pure thiadiazole and pure cefazolin (sodium
30salt or free acid) The method takes advantage of the difference
— 11 —




CH— CH ^H; N —  N
f/’ ~  \ c ^  g J ! - C H 3
COOH
(1:4)
and the thiadiazole moiety of cefazolin; the nmr signals appear 
at 62.54 and 62.84 ppm respectively. The authors claim that this 
technique avoids the potential weighing errors inherent in the use 
of an internal standard.
Cephalexin (1:6A) may be present in a given lot of cephradine 
(1:6B) as an impurity fron the synthesis of (1:6B) or as a decompo­
sition product of(1:6b). An nmr method to determine quantitatively 
the presence of cephalexin in cephradine has been reported by 
Warren at The method is applicable to the chemical itself
as well as to capsules and oral suspension formulations. The 
determination is based on the nmr signal from the five aromatic 










level is ±0.18%. The time required to carry out a single analysis 
is about 10 mins, and five analysts can be done in about 0.5 hr.
Another example of the use of nmr in quantitative analysis is 
reported^^ for a four-component mixture of phenylglycine derivatives.
A rapid, accurate, and precise nmr analytical method for the analysis 
of phenylglycine (1:7A), dihydrophenylglycine (1:73), tetrahydro- 
phenylglycine (1:70) and cyclohexylglycine (1:7D) in combination 
with each other has been developed. The method is based on the 
integration of the nmr signal characteristic of each component relative 
to the signal from tetramethy1-ammonium bromide, which is added 




HIaC —COOH rliHj —COOHNH(1:7C; (1:7D)
the four components is required. 2% DCl solution was used as the 
solvent.
Table 1:1^  ̂Chemical shifts of signals characteristic of individual 
components.





Tétraméthylammonium bromide 3.36 12
— 14—
The analysis of several other pharmaceuticals is listed in 
Table 1:2, page 15. All authors of published reports advocate
that the nmr method has an accuracy, precision, and . sensitivity 
comparable to the existing methods. The method offers the ad­
vantage over others of being rapid and specific.
Most of the analysis is based on the selection of a part of
the spectrum where there is no overlap of signals. The method is
limited to only those compounds or preparations whose signals do
not overlap in the entire spectrum. This means that only pure
single compounds and certain mixtures can be analysed by this method.
Moreover, apart from protons in close proximity to electronegative
2centres or those attached directly to Sp hybridized carbon atoms,
which give rise to resonance in characteristic low field positions,
most other resonances occur in the 60.5 - 2.5 ppm region. This
gives rise to coincident peaks from formally non-equivalent protons
59and non-analysable spectra . Many of these problems can be solved
by the use of lanthanide shift reagents. Other techniques generally
available include spectrum simplification by irradiation- of the
samples with a second radiofrequency (a spin-decoupling experiment)
and variation of the ambient probe temperature, but these methods
have not been applied in the quantit ative analysis of pharmaceutical 
49products . Larger magnets (higher rf powers) simplify spectra 
and resolve peaks close together. However, this advantage is 
offset by the high cost of the instruments. Spectra may often be 
simplified by removing interfering OH and NH proton signals through
49addition of a few drops of heavy water (D^O) or gaseous acid vapour 
The use of D^O as a solvent eliminates the interfering NH and Oti signals
-15-




Chloral Hydrate in soft Gelatin maleic 0.6% 32
Capsules acid
Trimethadione in various dosage t-butanol ±0.3% 33
forms
Methsuximide and Phensuximide HMCTS 0.6% or 14
in capsules less
Acetazolamide and its sodium 
.salt in various dosage forms t-butanol 0.73% 16
Thiotepa benzoic acid 0.6% 31
Carbromal and Bromural in HMCTS Carbromal=0
s r  "Tablets Bromural=0.
Amyl Nitrite in Inhalant biphenyl- or ±0. 5 10dosage form benzyl-
benzoate
Pentylenetetrazol in tablets 
and injectables HMCTS 0.7% 34
DMSO in solutions and ointments methanol 0.7%^ 6
Meprobamate in tablets maIonic 
acid
0.9% 35
Polydimethylsiloxane in various hexamethyl- 0.2 36dosage forms benzene or p-
dichlorobenzene
Glutethimide in tablets HMCTS ±0.97 37
Cacodylate injections succinic acid ±2.3% 38
Aminophylline in tablets t-butanol 0. 5% 39




Small sample size has been a problem in nmr quantitative analysis 
due to the relatively low sensitivity of nmr spectrometers. The use 
of a computer of average transients (CAT) and glass micro cells 
has, to a large extent, solved this problem. For CAT a spectrum is 
scanned repeatedly a preselected number of times. The signal out­
put from the spectrometer is stored and accumulated by the computer 
which presents a final spectrum with a total signal proportional 
to the number of passes through the spectrum and with the noise 
accumulated as the square root of the number of passes. This gain 
in signal to noise ratio and the build up of sample signal produces 
an nmr spectrum on microgram quantities of sample. The technique 
has been used for the determination of Q.l mg of barbiturate mixtures 
and for the analysis of 0.05 mg gas liquid Chromatography (g.l.c.) 
fractions from a commercial terpene fraction^^. CAT has also found 
application in biological systems^^.
Another problem with nmr quantitative analysis is the possible
interference from the drug excipients, ^^C satellites and spinning
side bands. Fortunately cases of interference from drug matrix
49are said to be rare . Most of the exipients are insoluble in
the solvents used for the analysis and are therefore filtered off.
Spinning side bands can often be eliminated by careful adjustment
of the sample spinning rate. The usual spectrum of ^̂ CII consists
of one large peak flanked on both sides by a small one due to the ^^C
coupling with the proton. Since the natural abundance of ^^C is
1.108%, each of the small peaks has 0.55% of the intensity of the
large one. It is therefore possible to correct for the ^^C satellites
2 8A procedure for the correction has been reported *
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Reviews on the use of nmr in pharmaceutical analysis have been
48, 49 41 9, 42 43presented by Rackman , Casy , Parfitt and Philipsborn
5A book on nmr quantitative analysis by Kasler has been published.
A vivid account of the applicability of nmr spectroscopy to regula-
44tory drug analysis has been given by Kram and Turczan . Articles
45-47by Alexander and Koch are also relevant to nmr quantification.
Many other articles on nmr quantitative analysis have been reported.
52 53These include analysis of quinidine and hydroquinidine ' , amyl
nitrite^^, p-hydroxybenzoates^^, diglycerides^^ and barbiturates^^.
1-2 Lanthanide Shift Reagents
18Spectral simplification by the use of solvents and transition 
metal complexes as shift reagents have long been observed but these 
were of no use to the analytical chemist because their induced shifts 
were too small to be of any practical value. Moreover, due to the 
relatively slow electron spin relaxation times of the transition metal 
ions, line broadening^^ resulted in the loss of signal multiplicity 
from which much of the structural information is derived^^. The real 
break-through came in 1969 when Hinckley^ discovered that the addition 
of the pyridine adduct of Trisdipivalomethanato europium (111) 
[e u (DPM)^ (1:8) to a solution of cholesterol in carbon tetrachloride 
caused a downfield shift in the spectrum of the steroid. He found 




larger than for those protons further removed and there was an 
absence of line broadening effects.
The findings of Hinckley stimulated the interest of many workers 
and in 1970 Saunders and Williams^^ prepared a pyridine-free complex 
of (1:8) and found that the absence of pyridine increased the shifts 
in the spectrum of cholesterol four-fold. It is considered that 
pyridine functioned as a competitive inhibitor for association with 
the substrate which decreased the induced shift.
1.2.1 Mechanism of Lanthanide Induced Shift
The chemical shift change (A6) caused by addition of a para­
magnetic species can be divided conveniently into three terms^^'^^'^^'^^ 
AÔ = AÔ(contact) + AÔ(dipolar) + Aô(diamagnetic)
The contact interaction involves direct delocalization and/or spin 
polarization of the unpaired electron via the molecular orbitals of 
the substrate ligand. As a result, the unpaired electron spin 
density is spread over a number of atomic sites in the ligand, 
thereby inducing a contact shift (i.e. through covalent bond formation). 
Coupling between the electron and nuclear spins does not cause ob­
servable splittings because of rapid relaxation of the electron spin.
The field experienced by the nucleus being observed is a weighted 
average for opposite orientations of the electron spin. This is 
not zero since the thermal populations of the electronic energy levels 
are not equal. The resultant shift can be to high or to low field, 
depending on the sign of the electron-nuclear coupling constant.
Since contact shifts are caused by the transmission of unpaired 
electron spin density through bonds, they are observed most extensively
-19-
in ligands with delocalized it systems. In ô-bonded systems they 
are rapidly attenuated with increasing separation from the metal 
ion.
The dipolar, or Pseudocontact shift, arises from secondary mag­
netic effects generated by the magnetic moment of the paramagnetic 
ion, and are transmitted through space. The induced pseudocontact 
shift (A6) of an axially symmetric molecule is expressed by the 
following equation (McConnell-Robertson equation^^).
AÔ (dipolar) x(3Cos 9-1) ....(1:10)
where 'r ' is the distance vector joining the metal cation to the 
particular nucleus (Fig. 1:1), '0' is the angle between that vector
(r) and the line connecting the metal ion and the co-ordinating 
atom (N) (i.e. the principal symmetry axis), so that 6 is the H-Ln-0
angle for the protons in cin alcohol; ' x ' is a constant for any 
given metal adduct at a given temperature and is dependent on the 
magnetic anisotropy of the ion.
Fig. 1:1 Co-ordination of Lanthanide ion with a compound.
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The pseudocontact shift is clearly a powerful source of structural 
information provided that it can be separated from other contributions 
to the observed shifts.
The third term (diamagnetic) encompasses all factors not result­
ing from the paramagnetism of the metal ion. While this term is 
frequently much smaller than the others, it cannot be ignored if 
accurate values of the pseudocontact shift are being sought. The 
Lanthanide shift reagents produce their effects mainly through the 
pseudocontact shift mechanism^^. However, contributions from con­
tact interaction is possible, particularly for protons attached to
64the carbons nearest the lone pair bearing atoms . Contact shifts 
depend on the overlap of orbitals containing unpaired electrons with 
ligand orbitals. For the transition metal ions with unpaired d 
electrons, contact shifts are sometimes several kilohertz. The 
unpaired f electrons of lanthanide complexes are in compact orbitals 
shielded from ligands, so that contact interactions are smaller 
or even absent. Contact shifts are primarily arsource of infor­
mation about electronic structure whereas pseudocontact shifts can 
be related to geometrical structure. Thus, through the use of 
lanthanide induced shifts molecular geometry can be elucidated.
1.2.2 Factors affecting the lanthanide (pseudocontact) induced shift
The magnitude of the induced shift (5A) depends on several 
factors :
(a) Temperature: The effect of temperature on lanthanide induced
shifts has been extensively studied^^. Generally, a decrease
— 21—
in temperature increases the magnitude of the shift. Armitage
and Hall^^^' were the first to report increased LIS at
lower temperatures. Dependence of LIS on the inverse of the
absolute temperature have been observed over the temperature
range - 30 to 90°C^^, but it has been stated that in any single
molecule all the protons may not always respond uniformly to
70, 115temperature changes Bennett and Schuster have reported
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Fig. 1:2 LIS of three protons of Obacunone (1:19) (Eu(fod)^/ 
substrate = O.ôJ as a function of temperature^^.
(1:19)
(b) Distance: The nearer a proton is to the site of co-ordination,
the greater the shift. An excellent illustration to this
point is given by shifts observed in the n-heptanol (1:9)
64spectrum after addition of E u (dpm) The order of the
HO - CH - CH - CH^ - CH^ - CH^ - CH^ - CH^
A B C D E F G
(1:9)
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induced shifts was as follows:
A > B > C > D > E > F > G
2(c) The Geometric term (3Cos 9-1): The angle term in equation (1:10)
determines the direction of the shift. Generally, Eu shifts
downfield and Pr upfield. However when 0 is between 125.3° and
54.7°, the induced shifts will be in the opposite direction to
the normal shifts, e.g. upfield for Eu and downfield for
This reversal in the direction of the shift corresponds to the term 
23Cos 0-1 becoming negative for this range of angles. This 
accounts for the occasional observation that as one adds a shift 
reagent such as Eu(fod)^ (lilOE), most peaks are shifted down­
field, but some are shifted upfield or remain unchanged^^. The 
shift reversal has been observed for protons in cases where the 
substrate envelopes the metal ion^^.
(d) Ratio of shift reagent to substrate: At low concentration of
lanthanide shift reagent, a linear concentration dependence 
of the induced shift is observed which is used to control the 
magnitude of the shift.
1.2.3 The Shift Reagents
The Lanthanide ion forms a complex with an organic molecule to 
form the Lanthanide shift reagent (LSR). The most useful complexes 
are g^diketone derivatives. These are often air stable and soluble 
in organic solvents, and have very simple nmr spectra. The LSR 
consists of a six co-ordinate metal complex which readily expands 
its co-ordination number in solution by accepting further ligands.
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These complexes behave as Lewis acids, binding basic substrates as 
labile ligands. Owing to the magnetic interactions with the metal 
ion in the complexed substrate, the nmr positions of the associated 
nuclei in the complex differ from those in the uncomplexed state.
The equilibrium in solution between these species is rapid on the 
nmr time scale so that only a single average signal is recorded for 
each nucleus in the different environments (an exception is the use 
of Eu(fod)^ with dimethyl sulphoxide in deuteriomethylene chloride 
at -80°C in which slow chemical exchange is reported^^). These 
shift reagents complex with a wide variety of substrates and the 
complexes are soluble in most of the solvents normally used for nmr. 
The solutions are stable but decomposition is caused by compounds 
with acidic groups such as carboxylic acids and some phenols. In 
these cases suitable derivatives must be prepared^^.
Several LSRs are now available. Each LSR has advantages and 
disadvantages depending on the substrate used and other factors. 
However, it appears that those prepared from Europium (Eu) are often 
superior to the others. Even though LSRs prepared from other metals 
of the lanthanide block (Ln^ ) may cause greater shifts than Eu, they 
are of limited application because of their serious line broadening. 
Praseodymium (Pr) shift reagents are the next most superior LSRs. 
Their shifts are larger than those caused by europium, compensating 
for line broadening. They induce upfield shifts which make them 
useful complementary reagents. A disadvantage of Praseodymium 
and other shielding LSRs, however, is the added complication of 
crossing-over of resonances, which confuses analysis in some cases.
—24—
(1:10)
1:10A R = R' = CH
1:10B R = R" = C^H6 5 CH.





R = CF^CF^; R' = CH^ -
/
CH3 CH.
-  IR = CF^CF^CF^; R' = CHj ^
CH.
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The following are some examples of Europium-^-diketone chelates 
(their structures are given on page 24 ): Tris-(acetylacetonato)
europium (111) Eu(acac)^ (l.lOA); Tris-(dibenzoylmethanato) 
europium (111) Eu(dbm)^ (1:10B); Tris-(1,1,1-trifluoro-5,5- 
dimethylhexane-2,4-dionato) europium (111) Eu(fhd) (1:10C);
Tris-(1,1,1,2,2,-pentafluoro-6,6-dimethyl heptane-3,5-dionato) 
europium (111) Eu(pfd) (1:10D); Tris-(1,1,1,2,2,3,3,-heptafluoro- 
7,7-dimethyloctane-4,6-dionato) europium (111) Eu(fad)^
(1:10E).
By virtue of their Lewis acidity and their solubility in common
nmr solvents, the fluorinated derivatives of the LSRs give larger
shifts because of the stronger binding in the complex. The greater
the number of fluorine atoms in the molecule, the larger the induced
shift. Thus, the order of the shifting power of the above mentioned
LSRs is Eu(fod)^ > Eu(pfd)^ > Eu(fhd)^ > Eu)dbm)^. The extent of
the induced shift also depends on the nature of the functional
group in the substrate. Greater shifts are caused by functional
64groups which are most basic . Functional groups give characteristic
shift magnitudes in the order, NH^ > OH > C = O > CHO > -O- > COgR >
59-CH . This order reflects the dissociation constant of the
corresponding substrate-reagent adduct and, to a smaller extent, the
geometry (distance and angle) of the protons with respect to the
central metal-ion^^. Imines, azobenzenes, halides and nitro compounds
59 69are not affected by LSRs ' . In the case of functional groups
consisting of two possible donor atoms, co-ordination is thought to
occur mainly with the oxygen atom when present. For example, amides
64co-ordinate at the oxygen atom
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Where a substrate contains more than one functional group it
is obvious that co-ordination with the LSR will occur at the most
basic centre. However, some co-ordination at the other centres is 
72also likely . Where the most basic centre is attached to a:bulky
group, steric hindrance prevents the co-ordination at that centre.
The greatest shift in 4-phenoxy butylnitrile (1:11) is obtained
from the methylene group to the cyano group, indicating that the
72complex is formed through the nitrile and not the oxygen atom
OCHzCHzCHzCN
(1:11)
Lanthanide chelates are very hygroscopic and should be stored 
over a suitable desiccant (e.g. P^O^) in vacuo. On absorption of 
water, the chelates usually become white solids and their shifting
power is drastically reduced. The anhydrous (dpm)^ chelates should
61  ̂have the following colours : pale green (Pr), white (Sm, Tb, Yb,
Gd, Dy, Tm, Lu), Pale yellow (Eu, Ho), red (Ce), violet (Nd), and
pink (Er).
As in all nmr analyses, the choice of solvent is important. 
Here, the solvent should be capable of solubilizing the chelate, 
the substrate, and the complex formed between the two without inter­
acting preferentially with the chelate. Thus, for Ln (dpm)^ and 
Ln(fod)^, solvents with strong Lewis base properties (e.g. ROH,
R^SO) are precluded. CCl^ and CDCl^ are the most common solvents 
employed. For substrates which are insufficiently soluble in non­
-27-
polar solvents, lanthanide salts can be used. The induced shifts 
when these reagents are used in polar solvents are very small be­
cause the solvent itself may co-ordinate to the reagent. Lanthanide 
salts, notably the hydrated chlorides, nitrates and perchlorates, 
have been used as shift reagents in such solvents. The induced 
shifts tend to be smaller than those observed with the ^-diketonates 
because hydration reduces the acidity of the lanthanide ion^^. Sol­
vents which have been used include DMSO-d, D^O/ deuteroacetone, 
deuteromethanol and deutero pyridine^^' . Europium trichloride
74has been used in dimethyl sulphoxide to study polyfunctional steroids 
With the hydrated lanthanide ions, most shifts induced by europium 
are to high field and those by praseodymium are to low field whereas 
the reverse is the case with the ^-diketonate complexes (see page 22). 
For quantitative structural studies the salts have some disadvantages 
compared with the ^-diketonate complexes. As the lanthanide ion 
is not surrounded by bulky ligands,contact shifts are likely to be 
more important.
Tricyclopentadienyl lanthanide complexes are an additional class 
of shift reagent^^. They are relatively strong acids and form stable 
and soluble 1:1 adducts with a variety of donors. The induced
shifts in these adducts may be very large (40 to 50 ppm). Unfortun­
ately the complexes are extremely sensitive to air and water, which 
limit their usefulness. •
Lanthanide shift reagents have helped solve a variety of 
structural problems including structure elucidation, detection and 
estimation of isomeric impurities'^^, conformational analysis.
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separation of overlapping signals, absolute configuration of closely 
193related compounds and the sign determination of spin-spin coupling 
77constants . The chiral derivatives of the LSRs are used for the 
direct optical purity determination of mixtures of enantiomers.
1.2.4 Chiral Lanthanide Shift Reagents - Determination of Optical
o  ■
Purities of Enantiomers 
Enantiomers are identical in all respects except in the spatial
arrangement (chirality) of the atoms attached to the optical centre.
Thus, they have identical physical and chemical properties (except 
that they have equal but opposite optical rotations). Their nmr 
spectra are also identical in non-chiral solvents.
The optical purity of a substance is the ratio of its specific 
rotation (a) to the specific rotation (A) (Absolute rotation) of 
the pure enantiomer.
Optical purity = ....(1:11)
% optical purity = ....(1:12)
Optical purity has the same value as the enantiomeric purity which is 
defined as the measure of the excess of one enantiomer over the 
other. Thus
1-dEnantiomeric purity = ....(1:13)
% Enantiomeric purity = ....(1:14)
where *1' and 'd' are the mole fractions of the enantiomers.
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The most common methods for optical purity determinations in­
clude polarimetry, which measures the optical rotation (a) of the 
compounds, chromatography, particularly , and more
recently HPLC^^ ^^,and nmr, the most recent technique. Other 
methods, less extensively employed, include isotope dilution^^, 
kinetic resolution^^' , and calorimetric methods^^. The nmr
method has been described as the most convenient and simple way
93to determine enantiomeric purity
Before the advent of chiral lanthanide shift reagents (CLSR), 
two methods were used to determine the optical purities of enan­
tiomers by nmr. The first one was through the formation of di- 
astereoisomers and the second through the use of chiral solvents. 
Diastereoisomers have different physical properties and hence diff­
erent nmr spectra. In principle, the optical purities are deter­
mined by linking the enantiomers to optically pure enantiomorphs 
of a suitable reagent and examining the nmr spectrum of the total
g
diastereoisomeric mixture . For the method to be successful, 
chemical shift differences between diastereoisomers must be suff­
iciently pronounced and care must be taken to ensure quantitative 
reaction of both enantiomorphs (so that the diastereoisomers ratio 
exactly reflects the enantiomeric ratio) and also that no racémisation 
or equilibrium process occurs. These two requirements are met 
by the use of an excess of optically pure chiral reagents and the correct 
sequence of the reaction process. A substantial literature is
available on nmr determination of optical purity by the method of
94,95 ,96diastereoisomer formation, particularly by Raban and co-workers 
Jacobus and Raban describe the determination of the optical purity
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of o^-phenylethylamine (L:12A) and (1:12B) by converting it into 
a mixture of diastereomeric amides (1:14A and 1:14B) with optically 
pure 0-methylmandeloyl chloride (1:13). The two c-methyl groups 
(as well as the other corresponding groups) in (1:12) are enantio- 
topic and consequently have the same nmr chemical shift (the signals 
from the groups are isochronous). By contrast, the c-methyl groups 
(as well as the other corresponding groups) in (1:14) are diastereo- 
topic and as a result have different nmr chemical shifts (the 




























The relative intensities of any of these sets of signals are in 
proportion to the relative abundances of the two diastereoisomers , 
and the ratio of the integrated intensities (R) can be used to 
calculate the optical purity (OP) using the following equation:
OP (%) R-1R+1 X 100  (1:15)
— 31—
(R)-0-methylmandelic acid (1:15) has been used as a chiral deriva-
97tising agent for optical purity determination of secondary carbinols
Another reagent, o_-methoxy-o^-trifluoromethylphenyl-acetic acid
98(1:16), introduced by Mosher , has many advantages over (1:13) 
and (1:15). Mosher's reagent (1:16) generally exhibits excellent
/ — OCH,  / T " ^  f C H ,
COOH COOH
(1:15) (1:16)
separation of diastereotopic fluorine and proton resonances, marked
stability to racémisation of derivatives under severe conditions,
and the presence of a trifluoromethyl group permits the use of
fluorine nmr. This reagent has been applied to the determination
98of optical purity of a series of secondary amines and alcohol ,
99 100phenylethylene glycol , and phenyltrimethylsilylcarbinol
The second method of nmr optical purity determination is based
on the principle that enantiomers give non-identical nmr spectra in
chiral solvents. Thus^ diastereomeric interactions are involved
rather than with diastereomeric compounds. When a racemic solute
(E , E ) is dissolved in a racemic solvent (S ,S ), transient 
-t —  +  —
diastereotopic solvates are formed. Since solute-solvent inter­
actions are averaged on the nmr time scale, the diastereomeric
-32-
interactions in the two enantiomeric solvates sets E S  - E S  and+ + + -
E S  - E S^, produce.‘Only one set of solute signals. However, in 
an optically active solvent (S_̂ ) only one set of diasteriomeric 
interactions (E^S^ and E S^) exists and enantiotopic nuclei of 
the solute are then unequally screened. These nuclei, in principle, 
should show different chemical shifts, and integration of their 
resonances would then provide a direct measure of the enantiomeric 
purity of the solute. This method has been exployed extensively by 
Pirkle and co-workers^^^'^^^. Pirkle and Beare^^^ determined the 
enantiomeric S:R ratio of amino acid methyl esters by observing 
their nmr chemical shift differences in optically active 2,2,2- 
trifluorophenylethanol. This solvent has been the most useful 
reagent for a variety of amines, esters and sulphur and phosphorus 
compounds. An important feature of this technique is that enantio­
meric configurations can be correlated with chemical shift differences 
and thus absolute configurations can be established^^^ However,
the method is limited to polar solvent-solute combinations because 
non-equivalence results from diastereomeric solute-solvent inter­
actions. Shift differences tend to be small (< 0.04 ppm) which 
also limits the usefulness of this technique^^^. Optically active 
nmr Lanthanide shift reagents give a greater induced shift.
1.2.4.1 The use of Chiral Lanthanide Shift Reagents (CLSRs)
4Whitesides and Lewis first observed that enantiomeric amines 
dissolved in achiral solvents containing 3-(t-butylhydroxymethylene) 
d-camphorato europium (111) (1:17A) gave relatively large frequency
differences between corresponding resonances (compared with the two 
previous methods described above). The observations indicated that
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(1:17A) and related compounds (1:17A-D) could provide the basis for 
a useful method for determining the enantiomeric purity of certain 
compounds for which procedures based on diastereomeric interaction 
between solute and solvent fail. In practice the utility of (1:17A) 
is restricted to applications involving relatively basic and un­
hindered substrates (e.g. primary and secondary amines), and fails 
with less basic substances. A large number of chiral shift reagents 
have been synthesised which demonstrate the general applicability 
of these materials to the determination of the enantiomeric purity 
of relatively non-basic substances. As with the ordinary lanthanide 
shift reagents, the halogenated derivatives of the chiral LSRs are 
superior to the non-halogenated ones^^' 1^4, 105^ addition to
fluorination, the potential of chiral shift reagents can be improved 












Shifts over 1 ppm have been observed using the fluorinated CLSRs^^. 
By proper choice of shift reagent and conditions, shift differences 
for at least one set of enantiotopic protons are often large enough 
and sufficiently separated from other signals to allow enantio­
meric compositions to be determined directly from relative peak 
areas.
A simple nmr method was developed by Reisberg, Brenner and 
Bodin^^^ for the determination of the enantiomers of 7-chloro-3,3a-
dihydro-2-methyl-2H, 9H-isoxazolo ^3,2,-bJ 3^ benzoxazin-9-one
(1:18) using (1:17C). The Eu(hfbc)^ causes the doublet assigned 
to the protons of the 2-methyl group, which normally appears at
CH
(1:18)
about 1.5 ppm (5), to split into two pairs of doublets and to shift 
downfield to about 2.0 - 3.5 ppm. The downfield pair of doublets 
(2.5 - 3.0 ppm) re presents the two enantiomers present in one 
racemate, designated as the ^  form, while the upfield pair (2.0 - 
2.5 ppm) represents the enantiomers of the racemate designated as 
the o-form. From the integration of the area under the doublets, 
the relative concentration of all four enantiomers was determined. 
It is interesting to note that with Eu(fod)^ the methyl group of 
both 2" and forms of (1:18) appears as a pair of doublets in 
the 2.5 - 3.5 ppm region, but the doublets are not split into two
-35-
pairs as seen with CLSRs^^^. The hfbC (1:17C) chelates have been
found to induce larger shifts than the facam (1:17B) chelates.
However, shift differences for enantiomers are not consistently
larger for a particular reagent. The magnitude of non-equivalence
vary with the shift reagent: substrate ratio in unpredictable
104ways . The properties of these CLSRs are similar to the ordinary 
LSRs.
Accurate knowledge of optical purities is important in the manu­
facture of pharmaceutical products where the presence of one enantio­
mer in the drug might render the product toxic or of modified 
pharmacological activity and also in the area of polypeptide syn­
thesis , where a small amount of optical impurity in the monomeric
92starting material can lead to a polymeric product of low homogeneity 
It is therefore essential to have a simple, fast and accurate method 
of determining optical purities. CLSRs afford a powerful means 
of analysing optical purity and offer a much more convenient altern­
ative to the previous methods.
PART 2
2. OPTICAL PURITY (ENANTIOMERIC RATIO) DETERMINATION 
EMPLOYING CHIRAL LANTHANIDE SHIFT REAGENTS, AND 























































At low molar ratios, incremental addition of a chiral lanthanide
shift reagent ^CLSR^ induces a differential shift proportional to
the amount of shift reagent. As seen in figure 2.1 (page 36)
incremental addition of Eu(facam)^ ^  ̂ .3 to dl-Ephedrine (2:3) in benzene
(d̂ ) almost completely separates the N-CE^ signals belonging to the
d- and 1-forms. It is possible to achieve complete separation of
the two isomers %as in the case of tetramisole (Section 2.2.^,
but in most cases complete separation is not achieved for the
following reasons:
(1) Broadness of the resonance peaks with increase in reagent 
concentration;
(2) Saturation at the co-ordination centre;
(3) Merging of the resonance signals under study with other 
resonance signals, either from the same molecule or from 
the reagent;
and (4) Insolubility of the shift reagent in the solvent at' high 
reagent concentration.
The first factor is the most important.
The use of lanthanide shift reagents is almost always associated 
with broadness of the resonance peaks. In all the compounds studied, 
a plot of the broadness (the width at h height) against the molar 
ratio ( Reagent / Substrate ) gave a linear relationship. A typical 
plot of such a relationship is represented in figure 2.2 (page 38) 
using the results obtained from Propranolol (2:5). The extent of 
the broadening depends on how close the particular proton group under 
























































































complete separation of the two signals belonging to the two isomers, 
and integration is not feasible. Three techniques have been devised 
to overcome this problem:
(i)The base line technique;
(ii)The chemical shift difference (6v) method;
(iii)The peak height difference (6h) method.
(i) The base line technique
The * base-line' technique involves a consideration of two nmr 
bands assigned to the same functional group of the enantiomers ( (+) 
and (-) ) under examination and which are not fully resolved in the 
presence of a chiral lanthanide shift reagent. This is illustrated 
in figure 2.3 (page 39 ). The distance (S) between the base line
(i.e. the true base line T) and the trough between the bands (false 
base line F) is proportional to 1 - % optical purity (0P)/100 at a 
constant reagent to substrate molar ratio. Therefore, a plot of 
the separation (S) versus 1 - OP/100 gives a linear relationship 
which can be used to estimate the enantiomer ratio.
The successful application of this technique depends upon three 
major conditions:
(1) There must be a constant reagent to substrate molar ratio 
( CLSR / Sample ) for all the solutions;
(2) The instrumental conditions must be constant for all the 
solutions. Since the method is subject to base-line 
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(3) The total concentration of the two isomers in the mixture 
must be the same for all the solutions for the calibration 
curve.
It is not necessary for all substrate concentrations to be identical 
in practice, provided all results are converted to a standard con­
centration for calibration. Figure 2.4 (page 41 ) illustrates the
relationship between the substrate concentration and separation (S) 
using results obtained from Ibuprofen. There is a linear relation­
ship between separation (S) and concentration so that once the 
separation (S) for one concentration is known, the separation (S) 
for another concentration can be calculated.
The base line technique has been subjected to a mathematical 
treatment which is presented in the appendix
ôh = (g(z)-f (z))Ôp - (gp)2
r  (z)
This mathematical expression is summarised by saying that the base line 
technique is based on an equation of two terms:
(1) a linear term and
(2) a quadratic term
The quadratic term may be substantial and the linearity of the graph 
(curve) may only hold on a small angle.
For the enantiomers (optical purity determination) (section 2.2) 
the base line technique gave a linear relationship in all the compounds 
studied. For the diastereoisomers (section 2.3) a linear relationship
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was also obtained. Even though in the case of quinine/quinidine 
a curve (a parabola) was obtained with the ordinary plot, the log 
plot gave a linear relationship (figure 2:48 page 178 ), On the
other hand, for the non-enantiomeric or non-diasteriomeric compounds 
(section 2.4) a curve was predominant except where the two compounds 
under examination had similarity in their molecular structure. For 
example in the case of paracetamol and benorylate a linear relation­
ship was obtained (figure 2:53 , page 187 ). It appears that
the linear term of the equation is predominant for compounds of 
similar structures such as enantiomers and diastereoisomers. For 
compounds of non identical structures the quadratic term becomes 
significant.
The base line technique for optical purity determination has 
been compared with other techniques such as integration, counting of 
squares and weighing of the paper under the peaks. The results ob­
tained using ibuprofen are given in Table 2.1 (page 44 ). The base 
line technique gave the best results with a % error of 0.79.
Where peak separation is incomplete, the base line technique gives 
the most acceptable results.
For very close signals, scale expansion can prove useful. The 
base line technique has been compared at three different scales on 
the Perkin Elmer R12B spectrometer. The comparison was made using 
a mixture of benorylate and paracetamol in CDCl^/DMSO(d^). Three 
scales - 10 ppm, 5 ppm and 100 Hz - were compared. The nmr spectra 
of paracetamol/benorylate (Mole ratio 1.953) were recorded five 
times on each scale. The separation between the two NCOCH^ signals
Table 2:1 Comparison of 
using results
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the base line 
obtained from
technique with other techniques 
ibuprofen (section 2.2.6)
ACTUAL % Optical Purity as found by : Order of
OPTICAL _ _ Counting of Base linePURITY integration squares Weighing technique accuracy
(%) A B C D
0.00 0.63 1.60 1.12 0.00 D>A>C>B
47.56 43.18 44.71 36.11 50.40 D>B>A>C
70.50 63.04 64.71 66.66 69.50 D>B>A>C
23.70 20.11 21.88 23.61 24.50 C>D>B>A
66.00 60.00 57.45 54.86 65.00 D>A>B>C
Av. % error 10.01 8.51 15.11 0.79 D>B>A>C
Table 2:2 Comparison of the base line technique at different scales.
using results obtained from paracetamol/benorylate (section
2.4.1)
SEPARATION (S) (mm) at:





21-5 26. 5 32.5
Mean 30.4 28.8 32.8
Standard Deviation 8.80 2.21 0.25
Coef. of variation 28.95% 7.80!% 0.77%
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was measured in each case. The standard deviation and the coefficient 
of variation were calculated for each scale. The results are given 
in Table 2:2 (page 44).
The results clearly show that scale expansion gives better re­
sults than on normal scale (10 ppm). On a scale expansion the 
peaks are broadened and the base line F is very stable. When a large 
amount of lanthanide shift reagent is used, scale expansion is not 
necessary because in this case the peaks are very much broadened and 
therefore have stable base line F. The slightest separation is 
enough for the base line technique if a scale expansion is to be 
employed. The base line technique is therefore an economical method 
with respect to the use of CLSR.
(ii) The chemical shift difference (6v) method.
For optical purity or diastereomeric ratio determination, the 
chemical shift difference ('Sv) between the two peaks under examination 
from the same proton group varies proportionally with the enantiomer 
ratio or the diastereomeric ratio. This is illustrated below*.
Isomer A Isomer B
6v % Optical purity
or ÔV 0£ Diastereomeric ratio
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Thus, a plot of ÔV against the optical purity or of 6v against the 




* where the quantity of isomer A is always smaller than isomer B.
The chemical shift difference method is applicable only when diast­
ereoisomers are formed. For that reason the method is also applicable 
to enantiomers in the presence of a chiral shift reagent since dia- 
stereoisomeric complexes are formed.
Diastereomers have different chemical shifts. The chemical 
shift is dependent on concentration of the substrate. Therefore a 
diastereomer at different concentrations will exhibit different chemical 
shifts for a particular group of protons. Hence a mixture of two 
diastereomers will exhibit different chemical shift difference (ôv) 
depending on the ratio of the two. This technique is not applicable 
to non diastereomers because the chemical shift difference (6v) between 
the two peaks under examination does not vary proportionally with the 
ratio of the two compounds.
This technique has been successful for all the enantiomers and 
diastereomers subjected to such analysis. It is interesting to note 
that even where the base line technique failed in the case of quinine
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and quinidine for the normal plot, the chemical shift difference 
method still gave a linear plot. The chemical shift difference, 
unlike the base line technique is independent of the total concen­
tration of the isomers. This means that there is no need to have 
the same concentration for all the solutions for the calibration 
curve. It is the molar ratio of the two isomers under examination 
which is important. Unlike the base line technique, the chemical 
shift difference is not affected by different instrumental conditions. 
The noise at the base line has no effect on the results.
(iii)The peak height difference (ôh) method
It has been observed that if the difference in height of the two 
peaks belonging to the same proton group of both isomers ( (+) and (-) ) 
is plotted against the optical purity, a linear relationship is ob­
tained. Though the idea of using a calibration curve is new, the 
theory behind the method is well known . Optical purity is given by
1-d
1+d
where '1* and 'd' are the heights of the resonance peaks belonging to 
the '1' and 'd ' isomers of the same chemical group, and 1 > d. This 
means that a plot of (1-d) against the optical purity must be a straight 
line.
The direct use of peak height as a means of nmr quantification 
is not entirely satisfactory and this will be elaborated in part 3 
of this book. Moreover, the peak height difference is not zero for 
many racemic compounds (see section 2.2). Therefore the use of 
the above formula for enantiomer quantification has serious limitations.
-48-
The peak height difference, like the base line separation (S), 
is dependent on the total concentration of the substrate, and the 
instrumental conditions.
All the three techniques - the base line technique, the chemical 
shift difference method arid the peak height difference method - had 
a correlation coefficient greater than 0.97 in all the compounds 
analysed. The accuracy and precision of the three techniques have 
been compared. A typical result obtained is represented in table 2:3 
(page 49). Although all the three techniques show acceptable accuracy 
the chemical shift difference method appears to be the most accurate, 
and with the least standard deviation. The main disadvantage of the 
techniques is the fact that the pure isomers or at least one pure 
isomer in addition to the racemate must be available for a calibration 
curve.
Derivatisation of compounds
Derivatisation of the compounds was sometimes necessary in order 
to obtain the optical purity. Derivatisation is essential where an 
appropriate signal is absent in the compound, the compound under 
examination possesses many co-ordinating groups and therefore gives 
broad and featureless peaks, or the compound is insoluble in any of 
the common solvents employed for the analysis (see table 2:4, page 51).
(i) Compounds with no appropriate signal
Two of the compounds - atropine/hyosyamine (2:21) (section 
2.2.10) and propranololt2:5) (section 2.2.3) - fell within this 
category. For atropine/hyosyamine, the N-CH^ signal appeared to
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Table 2:3 Comparison of the base line technique, 6v method and 





% optical purity obtained




0.0 0.2 0.0 0.0
25.6 24.7 25.3 25.0
50.5 49.0 50.7 51.2
70.3 70.8 70.0 70.6
Av. % error 0.75 0.20 0.53
Av. Standard Deviation 2.5 0.1 2.2
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be suitable at the initial stages. However, with the addition of 
the shift reagent (see section 2.2.10) the CH^ signals merged with 
the CH^ peaks. It was therefore necessary to use a derivative.
The most appropriate derivative was the tropic acid methyl ester.
In the case of propranolol, the spectrum showed signal overlap
/CH3
(with the exception of the C . signal)
CH3
Addition of a shift reagent did not result in resonance separation.
CZf]
The C signal could not be used in view of non-equivalent of
^0^3
the methyl signals which was revealed with addition of a shift reagent 
(see section 2.2.3). The N-acetyl derivative proved successful.
(ii) Compounds possessing many co-ordinating groups.
Compounds in this category present two problems, one of which 
is solubility and the other broad bands. Three of the compounds 
studied - salbutamol, dopa and rimiterol- fell into this category and 
therefore required derivatisation. Appropriate derivatives would 
increase their solubility in organic solvents like CDCl^, CCl^ and 
C_D , and also shield co-ordination sites by steric hindrance. Tri-
O D
methylsilyl (TMS) derivatives were found to be the derivatives of 
choice. N,N,-bis-trimethylsMyltrif luoroacetamide (BSTFA) (2:1)
was the silylating agent employed. With (2:1), trifluoroacetamide 
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(iii) Compounds with solubility problems other than those in (ii)
Fenoprofen (2:19) is an example in this category. Fenoprofen 
is formulated as the calcium salt. This salt is not soluble in 
any of the normal organic solvents used for the optical purity 
determination. It is also difficult to obtain fenoprofen(2 :19) from 
this salt by ordinary solvent extraction. The solution to the 
problem was the use of a derivative. In this case a methyl ester 
was formed directly from the salt and then extracted into chloroform.
The choice of a derivative obviously depends on the parent com­
pound itself but to make the analysis meaningful the derivative must 
be easy to prepare. The time involved must be short so that many 
determinations can be made in a short time.
There are many problems associated with the preparation of 
derivatives, the most serious of which is the possibility of racé­
misation of the pure isomer. One of the compounds - hyoscyamine - 
presented this problem. Alkaline hydrolysis followed by extraction 
with chloroform resulted in the formation of racemic tropic acid 
instead of the 1-form (see section 2.2.10).
Experimental difficulties and limitations of the method
One problem with the optical purity determination by use of
CLSR is the choice of solvent. Three solvents - CDCl^, CCl^ and
C D  - were used throughout the analysis. Though there was no 5 6
one solvent which could claim entire superiority over the others,
CCl^ was the best solvent for most of the compounds in view of the
large differential shift obtained. It is closely followed by C D »6 6
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^igures 2:13 (page 89), 2:17 (page 98 ), 2:3 6 (page 148) and 2:39 
(page 157 ) show the effect of solvents on LIS and ALIS of various 
compounds^. The least useful of the three solvents - CDCl^ - for 
differential shifts, was the best solvent with regard to solubility 
of the compounds studied, and CCl^ the worst. In some cases, a 
combination of solvents proved useful.
In general the best choice of resonance signal for the analysis 
is one
(i) with high sensitivity;
(ii) which is a singlet;
(iii) free from interference of other resonance peaks ;
(ivj close to the chiral centre and
(v) distant from the co-ordination centre.
The last requirement (v) prevents excessive broadening.
A preliminary study of the canpound under examination with non- 
chiral shift reagent was the practice adopted throughout the experi­
ments. This was to find out the behaviour of the compound in the 
presence of LSR and hence to avoid the use of the more expensive CLSR 
on less promising compounds.
The use of chiral lanthanide shift reagents for enantiomer quan­
tification is not always successful. Two out of the group of thirteen 
compounds studied could not be successfully quantified using CLSR. 
These were Rimiterol (3,4-dihydroxyphenyl-(2-piperidyl) carbinol 
(2:2) and Camphor (2:3).
— 54—
Rimiterol is a sympathomimetic bronchodilator. It is normally 





rimiterol presented solubility problems. Several spectra of rimi­
terol hydrobromide in many solvents were recorded but a broad and 
featureless spectrum was obtained in each case due to viscosity of 
the solutions. The solvents employed included: D^O, DMSO(d^),
CDCl./DMSO(d-) and C_D,/DMSO(d.). In view of the broad resonances, 3 5 6 6 6
complete assignment of the peaks was impossible. When working on 
rimiterol HBr, Sankey and Whiting^^^ obtained the nmr spectrum of 
a sample in D^O at 95^C. To obtain a good nmr spectrum of rimiterol 
HBr, a high temperature probe is required. Obviously 37°C is too 
low a temperature to obtain a good spectrum of rimiterol HBr. 
Attempts to use rimiterol itself also failed.
The failure of the rimiterol optical purity determination was 
due to viscosity of its solutions for nmr spectra. Paramagnetic 
material(s) in viscous solutions result(s) in broadened peaks. A 
variable temperature probe might be the solution to the problem.
For the camphor optical purity determination, the failure was 
due to lack of appropriate shift reagents since the shift reagents 
employed were camphor derivatives .
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(2:3)
Despite some limitations, the use of CLSRs for optical purity 
determination would seem to have some merit. It is accurate, 
fast and easy to use. For direct determination the method involves 
only four steps.
(i) Identification of resonance signals of the compound under 
examination.
(ii) Preliminary study with non chiral shift reagents.
(iii)Determination of ALIS with CLSRs.
(iv) THe optical purity determination.
CLSRs offer a quick method of checking the enantiomeric ratio 
of compounds. It is a highly sensitive method in the sense that it 
requires only a few milligrams of the sample for the analysis 
(unlike polarimetry). Where complete separation of the analytical 
peaks is obtained, as in the case of tetramisole (section 2.2.5), 
the analysis takes only a few minutes.
For direct determination of the enantiomeric ratio, the method 
is limited to compounds with few co-ordinating groups (not more than 
3). However, the method could be adopted for any compound through 
derivatisation and the use of appropriate shift reagents and under 
the right instrumental conditions. Where there is complete separ­
ation of the two resonance peaks belonging to the two isomers under
“56-
examination, and integration is used for the optical purity deter­




^ ~ ^ > - C h (o h ) CHNH CH;
(2:4)
Ephedrine (2:4) is an alkaloid obtained from species of Ephedra,
or prepared synthetically. It is a sympathomimetic amine with a
more prolonged, though less potent, action than adrenaline. Since
109the discovery of the Ephedrines in 1887 numerous articles have 
been published with regard to their structure^^^' conformational
analysis^^^' studies on their configuration^^^ and their prop­
erties, including biological activity. Though much work has been 
done on Ephedrines by the use of nmr, none includes the quantitative 
analysis by this technique. In this report an account is given on 
the potential use of nmr for the direct determination of their optical 
purities using chiral lanthanide shift reagents.
Before the optical purity determination, the Lanthanide induced 
shifts (LIS) of the various proton groups in Ephedrine were deter­
mined using Eu(fod)^ and Pr(fod)^. The results are shown in 
figure 2.5 (page 63 ) and in tables 2.5A and B (page 59). The 
differential shifts (ALIS or AAv) were also determined using Eu(facam) 
and Pr(facam)^. The results for this determination is shown in 
figure 2.6 (page 67) and in tables 2:5C and D.
The optical purity was determined using Pr(facam) in C D  and3 6 6
-58-
Table 2:5A LIS of the various proton groups in ephedrine in 
the presence of Pr(fod)^ in benzene
{^Ephedrine J = 0.45M
MOLAR RATIO LIS in ppm
Pr(fod)2 C--“ 3 N-CH3 CH-N 0-CH
ephedrine Ô Av Ô Av 6 Av Ô Av
0.00 0.74 0.00 2.10 0.00 2.54 0.00 4.71 0.00
0.060 0.04 0.70 0.84 1.26 1.68 0.86 3.85 0.86
0.093 -0.27 1.01 0.74 1.36 1.23 1.31 3.35 1.36
0.136 -0.64 1.38 0.67 1.43 0.67 1.87 2.78 1.93




E u (fod)2 C--“ 3 N-“ 3 0-CH
*Aromatic
protons
Ephedrine Ô Av Ô Av Ô Av Ô Av
0.00 0.67 0.00 2.05 0.00 4.68 0.00 7.15 0.00
0.045 0.90 0.23 1.97 -0.08 4.57 -0.11 7.00 -0.15
0.096 1.02 0.35 1.88 -0.17 4.52 • -0.16 6.85 -0. 30
0.136 1.11 0.44 1.81 -0.24 4.47 -0.21 6.75 -0.40
0.182 1.20 0.53 1.72 -0.33 4.46 -0.22 6.63 -0.52
0.240 1.39 0.72 1.56 -0.49 4.47 -0.21 6.47 -0.68
0.292 1.53 0.86 1.40 -0.60 4.75 +0.07 6.30 -0.85
*Average results for the aromatic protons
The ClfN resonances were broad and featureless 
-ve values indicate upfield shift.
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Table 2 : SC LIS and AAv of the C-CH^ signals of d and 1-ephedrins
in benzene using Pr(facam)
[dl-Ephedrinejj = 0.39M
MOLAR RATIO 1-isomer d-isomer AAv (ppm)6 Av 6 Av
0.00 0.74 0.00 0.74 0.00 0.00
0.076 0.05 0.69 0.18 0.56 0.13
0.119 -0.34 1.08 -0.16 0.90 0.18
0.153 -0.59 1.33 -0.35 1.09 0.24
0.182 —0.86 1.60 -0.57 1.31 0.29
0.212 -1.19 1.93 -0.86 1.60 0.33
Table 2:5D LIS and AAv of the N signals of d and 1-ephedrines
in benzene using E u (facam)^ 
[dl-Ephedrine] = 0.40 M
MOLAR RATIO 
Eu(facam)^ 1-isomer d- isomer AAv (ppm)
dl-ephedrine Ô Av Ô Av
0.00 2.10 0.00 2.10 0.00 0.00
0.065 1.91 0.19 1.98 0.12 0.07
0.090 1.84 0.26 1.93 0.17 0.09
0.108 1.77 0.33 1.89 0.21 0.12
0.120 1.75 0.35 1.88 0.22 0.13
0.172 1.64 0.46 1.81 0.29 0.17
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Table 2:6A Optical Purity determination of Ephedrine 
Shift reagent: Pr(facam)_
Solvent: ^6̂ 6 (0.7 mis) ^otal Ephedr ine^ = 0.30 M
*Molar Ratic>: 0.216 ± 0.004
Analytical peak: C-CH^ signal at -1.0 to -1.5 ppm
Optical purity Separation Peak height Chemical shift
{ OP • % 1 /c. mm ̂ 1 - ^ difference difference\ Vir /  ̂}  ̂o ; IIIIU ) 100 (5h; mm) (gv) (ppm)
0.0 4.70 1.00 -0.60 0.30
25.6 3.80 0.74 5.34 0.46
47.3 2.71 0.53 11.76 0.60
76.0 1.48 0.24 20.69 0.77
Table 2:6B Optical Purity determination of Ephedrine using peak height 
Shift reagent: E u (facam).
Solvent : benzene [TOal Ephedrine] = 0.30 M
*Molar Ratio : 0.11




purity (A; %) j  X 100(%)
0.00 0.00 100
10.13 10.20 99.31
21.77 21.95 99 2 * Molar Ratio ;
28.35 28.21 100.5
35.00 35.05 99 9 Reagent








Table 2:7A Effect of dilution with benzene on the LIS of ephedrine 
at E u (fod)^/ephedrine mole ratio of 0.159
Vol. of 5 5 C-CH- N-CH 0-CH
added -
(ml) Ô Av 6 Av 6 Av
Original 0.91 0.00 1.68 0.00 4.22 0.00
0.1 0.99 0.08 1.74 0.06 4.33 0.11
0.2 1.07 0.16 1.81 0.13 4.46 0.24
0.3 1.14 0.23 1.87 0.19 4.58 0.36
0.4 1.22 0.31 1.92 0.24 4.69 0.47
0.5 1.29 0.38 1.97 0.29 4.76 0.54
Table 2:7b Effect of dilution with benzene on the LIS of ephedrine
at Eu(fod) ^/ephedr ine molar ratio of 0,.212
Vol. of 6 5 C-CH^ N-CH3 0-CH
added (ml) 6 A V 6 A V Ô A V
Original 1.13 0.00 1.75 0.00 4.37 0.00
0.1 1.23 0.10 1.79 0.04 4.52 0.15
0.2 1.34 0.21 1.89 0.14 4.68 0.31
0.3 1.42 0.29 1.92 0.17 4.80 0.43
0.4 1.47 0.34 1.95 0.20 4.89 0.52
0.5 1.52 0.39 1.97 0.22 4.97 0.60
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Table 2:7c Effect of dilution of ephedrine in C^D^ at a molar ----------  5 6
ratio of 0.106 using Eu(fod)^








Original 0.90 0.00 1.84 0.00 4.41 0.00
0.1 1.00 0.10 1.93 0.09 4.53 0.12
0.2 1.04 0.14 1.96 0.12 4.61 0.20
0.3 1.05 0.15 1.98 0.14 4.63 0.22
0.4 1.05 0.15 1.98 0.14 4.67 0.25



































by employing the base line technique, ôv method and 6h methods.
The C-CH^ was used as the analytical peak. The results are given 
in figure 2.7 (page 68 ) and in table 2:6A (page 60 ). Direct peak 
height measurements were also used for the optical purity deter­
mination by the use of Eu(facam)^. The results are given in 
table 2:6B (page 60 ).
2.2.1.1 Results and discussion
Lanthanide induced shifts (LIS):
The problem encountered initially with the determination of LIS 
was the choice of suitable solvent. The use of solvents containing 
hetero atoms such as oxygen, nitrogen and sulphur were precluded in 
view of competition between the ephedrines and the solvents for the 
shift reagent. The most readily available solvents - CDCl^ and 
CCl^ - which are most often used with lanthanide shift reagents 
proved to be unsuitable. The ephedrines dissolved with difficulty 
in CDCl^ and CCl^ at room temperature, and in many cases crystallized 
out when inserted in the probe. Brownlee^^^ has reported that 
ephedrine base dissolved in CHCl^ or CCl^ forms its hydrochloride.
Benzene proved to be the most suitable. With Pr(fod)^ as the 
shift reagent and benzene (d̂ ) as the solvent, all the various proton 
groups gave upfield shifts which is expected from praseodymium.
(The results are shown in figure 2:5 and in table 2:5). The OH 
and NH moved together and the extent of LIS for the various groups 
indicated equal co-ordination at both O and N atoms. With Eu(fod)^ 
in benzene (d̂ ) the various groups (with the exception of OH, NH 
and C-CH^) showed upfield shift at Eu(fod)^/Ephedrine molar ratio
-65-
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below 0.3. Above this ratio, the CH signal gave a shift reversal.
At low molar ratio of reagent to substrate, the site of co-ordination 
appears to be both N and O . At higher molar ratios, the co-ordin­
ation is stronger at O than at the N.
LIS and ALIS with chiral shift reagents:
The results for the ALIS are given in figure 2:6 and in tables 
2:5C and 2:5D. With Pr(facam)^ as the shift reagent in benzene,
the N-CH^ and the C-CH^ gave differential shifts (AAv) for the 1
and d isomers. However, the signals were too broad particularly 
for the N-CH^ signal. It appears that with Pr(facam)^ in benzene, 
the co-ordination is stronger at N than at O, since the groups 
attached to the H (i.e. N-CH^ and CHN) gave the largest LIS. More­
over, they gave the most broadened peaks (line broadening a 1/r^)^^'^^, 
at the concentrations of the reagent used.
With Eu(facam)^ in benzene at the concentrations used, the N-CH^ 
gave two sharp singlets (figure 2:1 page 36 ). The C~CH^ also 
showed some separation. Of the two groups the N-CH^ showed the 
greater promise for analytical purposes, because the resonance peaks 
of the d and 1 isomers were well separated even at a E u (facam) 
dl-ephedrine molar ratio of 0.1. Higher concentration of the 
reagent is likely to give well separated peaks more suited to analysis 
but the presence of irrelevant resonance peaks (from the reagent) 
close to the N-CH^ peaks, and the possibility of the N-CH^ and C-CH^ 
peak overlap at higher reagent concentrations, indicates a reagent 
to substrate mole ratio of about 0.11 to be the most suitable for 
optical purity determination.
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Op tical purity determination:
For the peak height measurements the optical purity was calculated 
from the following formula :
=2 -optical purity = -— , - x 100
“2
where and are the heights of the N-CH^ resonance peaks of the 
1 and d isomers. The subscripts (2 and 1) indicate the higher and
lower peaks respectively. The results were satisfactory up to
optical purity of about 50% (see table 2:6B). Above that, unsatis­
factory results were obtained due to broadened peaks.
With the new techniques - (base line, ôv and Ôh) - a linear
relationship was obtained when the optical purity or 1 - % optical
purity/100 was plotted against the appropriate parameter. The re­
sults are shown in figure 2:7 and in table 2:6A.
Effect of dilution on the LIS:
During the course of the experiments it was observed that at a
fixed reagent-substrate mole ratio, incremental addition of the
solvent caused a downfield shift proportional to the amount of solvent 
added. This effect was independent of the nature of the reagent or 
solvent used but depended on the initial concentration of the reagent.
The results are given in tables 2:7A to C. (page 61 ) and in figure
2:8 (page 59 ) . This dilution effect has already been observed by
some workers^^^ but no explanation had been given for it. Tomic 
et observed the effect on cyclopropylmethanols with Pr(DPM)^
in CCl^, and CS^, when dilution with the solvent gave downfield shifts. 
Since praseodymium chelates normally give upfield shifts, the downfield
shift brought as a result of dilution might have been assumed to be
- o 7 -
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a reversal of shift. In the present experiments a europium chelate 
Eu(fod)^ was used on dl-ephedrine in benzene (d̂ ) and all proton 
groups in the molecule gave downfield shifts with dilution irrespective 
of their initial direction of shift. This effect, therefore, cannot 
be regarded as shift reversal. Irrelevant resonance peaks such as 
solvent peaks and peaks due to the reagent all moved downfield with 
dilution. The effect is greater at higher molar ratios.
2.2.2 PSEUDO EPHEDRINE
(2:5)
Pseudo ephedrine (2:5) is a diastereoisomer of ephedrine. It 
is a bronchodilator and peripheral vasoconstrictor. It is said to 
have a less vasopressor action than ephedrine and to cause little 
cerebral stimulation. It is used as a nasal and bronchial decon­
gestant, particularly in bronchial asthma^^^.
Like ephedrine, the optical purity of pseudo ephedrine has been 
determined by application of the base line technique, chemical shift 
difference and peak height difference methods. Pr(facam)^ was the
CLSR and C~CH^ was used as the analytical peak. The results are
-71—
Table 2;8A LIS of the various groups in pseudo ephedrine in
C-D using Eu(fod)_ b D j
[^-ephedrine] = 0.31M
MOLAR RATIO C-CH. N-CH- 0 Aromatic
E u (fod)^ CH protons
i/^-ephedrine 6 Av 6 Av 6 Av Ô Av
0.00 0. 65 0.00 2.00 0.00 4.03 0.00 7.17 0.00
0.072 0.67 0.01 0.96 -1.04 4.20 0.17 7.00 -0.17
0.135 0.73 0.07 0.81 -1.19 4.37 0.34 6.83 -0.34
0.205 0.76 0.10 0.62 -1.38 4.62 0.59 6.64 -0.53
0.275 0.80 0.14 0.40 -1.60 5.02 0.99 6.43 -0.74
-ve values indicate upfield shift
NH, OH and CH gave downfield shift.
-72-
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Table 2:9B Optical Purity determination of ijj-Ephedrine by peak 
height measurement
Molar.-Ratio: Reagent / ̂ -Ephedrine 0.075
Reagent: Pr(facam)^ ; [Pseudo ephedrine] = 0.30M
Solvent: COCl^/CD^ (1:1)i 5 6
Analytical peak : N-CH
Actual % Optical 
Purity (A)
% Optical Purity 
obtained (0) 0/A X 100% % Error
0.0 1.20 - -
9.70 10.98 113.20 13.2
14.44 12.56 86.98 13.0
23.31 20.67 86.81 13.2
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given in table 2:9B (page 77). The LIS and ALIS were also deter­
mined and the results are shown in tables 2:8A-E (page 71). A 
graph of ALIS is shown in figure 2:9 (page 80). The lanthanide 
shift reagents employed for the analysis were Eu(fod)^, Pr(fod)^, 
Eu(facam^ and Pr(facam)^.
2.2.2.1 Results and Discussion 
LIS and ALIS:
The, LIS using the various shift reagents in C^D^ were slightly 
different from those of ephedrine. This is obviously due to the 
different configurations of ephedrine and pseudo-ephedrine.
With the Eu(facam) in benzene (d_), the C-CH. and 0-CH signals gave3 5 3
differential,shift. The N-CH^ signal unlike that of ephedrine, did not 
separate.
It is interesting to note that pseudo ephedrine, in constrast
to ephedrine, is readily soluble in CDCl^. The LIS obtained in
CDCl are significantly different from those obtained in C^D . The 3 6 6
use of Pr(facam) in both benzene (d.) and CDC1_ resolved the N-CH_3 6 3 3
resonance peaks of the d and 1 isomers in addition to the C-CH^ and
the CH-0 resonance peaks. The separation appears to be much better
in benzene (d̂ ) than in CDC1_. In addition the differential shift 
6 3
of the 1-N-CH and d-N-CH resonance peaks is greater in C D  than in 3 3 6 5
CDCl^. Unfortunately, benzene (d̂ ) is not a good solvent for 
pseudo ephedrines with regard to solubility and cannot be used for
their routine analysis. A mixture of CDCl^ and C: D< (1:1) is the3 6 6
best solvent for this purpose.
-80-























































































FIG, 2•..II OPTICAL PURITY DETERMINATION OF PSEUDO EPHEDRINE
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The effect of dilution on the LIS of the various proton groups 
in pseudo ephedrine was similar to that of ephedrine. The results 
are shown in Figure 2:10 (page 80) and in table 2:10 ( p a g e  78).
Optical Purity determination:
Like ephedrine, the pseudo ephedrine optical purity determination 
by the base line technique, chemical shift difference and the peak 
height difference methods'gave linear graphs. The results are 
given in table 2:9A (page'76) and in figure 2:11 (page 31 ).
Using Pr(facam) in C D /CDCl (1:1) well resolved signals were 3 6 6 3
obtained for the N-CH^ at a molar ratio of 0.075. It was there­
fore convenient to use peak height measurement at that molar ratio 
for the optical purity determination. The experiment was success­
ful up to optical purity of about 30%. There was a constant error 
of about 13% in all levels of optical purity up to 28.1%. The 
results are given in table 2:9B. It is clear that the new tech­









(2:6) is a adrenergic receptor blocking agent developed by Black 
118e t a i . It is extensively used in the treatment of hypertension.
Propanolol is a mixture of (+) and (-) isomers
120
119 with only the
(-) isomer having _^-blocking activity^^^. The enantiomeric purity 
of propranolol has been determined by a combination of gas', chroma­
tography and mass spectrometry using a deuterium labelling technique 120
In this work/ the optical purity of propranolol has been deter­
mined using the N-acetyl derivative (2:7)and a chiral lanthanide 
shift reagent ^ E u ( f a c a m ) ^ T h e  optical purity determination was 
preceeded by the determination of the ALIS of the COCH^ belonging to 
(2:7). The results are given in tables 2:11 A and B (page 84 ) and 
in figures 2.13A and B (page 89).
2.2.3.1 Results and Discussion
The addition of shift reagents to propranohl resulted in broad­
ening of bands. There was no visible differential shift for the d 
and 1 isomers. In view of this/ it was necessary to use a deri­
vative for the optical purity determination. The N-acetyl derivative 
(2:7) proved'suitable for the purpose. The equation for the synthesis 
of (2:7) is given in Scheme 2:1. The yield (see section 2.6) was
p H  ^ C H ,
O C H aC H C H jN -C H
, , ( C H , C 0 ) ^ 0  ^





Table 2:11A COCH^ of N-acetylpropranolol ALIS in CCl^ using 
Eu(facam)^
[w-acetylpropranol] = 0.25M
*MOLAR RATIO (+) isomer (-) isomer AAv
6 Av Ô Av; (ppm)
0.00 2.10 0.00 2.10 0.00 0.00
0.183 3.07 0.97 2.92 0.82 0.15
0.276 3.64 1.54 3.42 1.32 0.22
0.367 4.15 2.05 3.87 1.77 0.28
0.521 4.70 2.60 4.39 2.29 0.31
Table 2:11B COCH of #-acetyl propranolol ALIS in CDCl and C D  3 3 6 6
using Eu(facam)^
n-acetylpropanolol = 0.25 M
CDCl^
tMOLAR RATIO AAv (ppm) MOLAR RATIO AAv (ppm)
0.00 0.00 0.00 0.00
0.159 0.10 0.189 0.00
0.260 0.12 0.404 0.00
0.357 0.17 0.465 0.01
0.493 0.15 0.540 0.02
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low. This might be due to the formation of the ester in addition 
to the amide since the OH was not protected from acétylation.
Non-equivalence of the isopropyl group:
The nmr spectrum of N-acetylpropranolol (figure 2.12, page 86) 
reveals non-equivalence of the isopropyl methyl groups (CH^ 3). 
In the spectrum of propranolol itself, a doubJet was obtained 
for the two methyls indicating equivalence of the two groups.
The equivalence of the isopropyl groups in propranolol is pro­
bably due to the fact that the lone pair electrons on the nitrogen 
are localized, and moreover, there is free rotation at the N-CH 
bond. On the other hand, when
HI ^ M e
R —  N— CH
^ M eo
acetylated the electrons are delocalized as shown below. The 
populations of the various conformers are not equal.
—88—
R —  KT\— CH
I *  " ^ M e




•  O  ^ M e
also




M ë ^  O -
The non-equivalence of the isopropyl group in certain mole­
cules has already been observed by many workers^^^ 127^ Four 
possible explanations have been proposed^^^ 127^
(1) Different conformers;
(2) Anisotropic effect of the carbonyl (C=0) group;
(3) Steric hindrance to rotation at the N - C bond;
(4) Inter/lntra molecular hydrogen bonding.
The isopropyl group methyl resonance could not be used for the 
purpose of quantification in view of the non-equivalence.
ALIS of the COCH^ signal:
Carbon tetrachloride proved to be the best solvent among the 
solvents employed (see figure 2.13A, page 89 ). A differential
-89-
FIG.2:13 A) EFFECT OF SOLVENT ON THE DIFFERENTIAL SHIFT OF OCHo SIGNALS OF
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shift of over 0.3 ppm was obtained in CCl^ at low molar ratio. 
The (+) isomer gave a larger LIS than the (-) isomer (figure 
2.13b , page 89). As seen in figure 2.13A, CDCl^ was not a
suitable solvent. From the LIS plots (figures 2.13A and B), it
appears that the Eu(facam)^ and the N -acetylpropranolol forms 
a 1:2 chelate.
Optical purity determination:
Figures 2:14 and 2:15, and table 2:12 show the results of the 
optical purity determination by the base line technique, the chemical 
shift difference method and the peak height difference method. A 
linear graph was obtained in each case, indicating the accuracy of 
the methods. Though a large AAv was obtained, complete separation 
of the peaks was not possible in view of the broadness of the peaks 
at higher molar ratios. For the same reason, integration and direct 
peak height measurements were not suitable. The simplicity of 
the base line technique, the chemical shift difference or peak 
height difference methods coupled with their accuracy makes them 









Salbutamol (2:8) is a sympathomimetic (selective amine used 
as a bronchodilator. It is extensively employed in the treatment 
of asthma.
The optical purity of salbutamol has been determined through 
the formation of its silyl derivative (2:8) and the subsequent 
application of the chiral^lanthanide shift reagent Eu(facam)^ and 
the base line technique, the chemical shift difference and the peak 
height difference methods. CCl^ was the solvent employed in the 
analysis.
Silylation has a wide range of applications in analytical 
chemistry. Two of its applications - blocking of reactive sites 
and altering of the solubility of materials^^^ have been em­
ployed here to aid the optical purity determination of salbutamol,
The direct use of CLSR for the optical purity determination of
salbutamol proved impossible because of the presence of the amino
group and the three hydroxy groups in the molecule (see section 2.1).
Salbutamol is not readily soluble in the common organic solvents used
for optical purity determinations when CLSRs are used. Salbutamol
is freely soluble in water and this makes its extraction from aqueous
132solution or plasma difficult. For these reasons, the analysis 
of salbutamol has been performed after conversion to a TMS deriva­
tive (2 :10) .
The equation for the silylation is shown in Scheme 2:2. The 
SiOC#2 signal was employed as the analytical peak. The results
—94—





CHgOSi AAv in Hz
CCl 4̂ ^6^6
0.4 1.6 2.3 3.3
0.6 2.4 3.5 4.0
0.8 3.2 4.7 4.8
1.0 4.0 - 5.7
1.2 4.8 7.8 6.5
1.4 5.6 8.1 7.6
1.6 - - 8.2





*Molar ratio : 1.20
Analytical peak CH^OSi signals atô4.6 - 5.4 ppm
% Optical 
purity(OP)









(R - S; mm)
0.0 1.0 7.0 0.10 0.9
25.0 0.75 5.2 0.14 8.0
50.0 0. 50 3 .7 0.17 15.6
75.3 0.25 1.8 0.19 22.2
100.0 0.00 0 .15 - 30.2
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for the ALIS and the optical purity determinations are shown in 
tables 2:13 and 2:14 (page 94) and in figures 2:17A and B, 2:18 
and 2:19 (pages 99-100).
2.2.4.1 Results and Discussion
The reaction of BSTFA with salbutamol gives two products -
(O -TMS)_ salbutamol (2:10) and Trifluoroacetamide (2:9). It is  ̂ 3
necessary that all the trifluoroacetamide be removed from the 
product by distillation before the use of the chiral shift reagent 
since trifluoroacetamide competes with the substrate for the 
shift reagent, thus decreasing the sensitivity of the method.
For the same reason, all the excess BSTFA must be removed (see 
section 1.2).
It is interesting to note that whereas in CDCl^ and in CCl^
the 3 0-TMS groups have different chemical shifts and therefore
appear as three singlets; in C D  all the 3 0-TMS groups areD 5
-96-
equivalent and appear as a singlet. The nmr spectrum of (2:10) 
in CCl^ is shown in figure 2:16 (page 97 ).
Lanthanide induced shifts (LIS):
Two singlets were obtained for the CH^OSi signal when the 
Eu(facam)^ was added, indicating the resolution of the S (+) and 
R(-) isomers. There was, however, no appreciable LIS for the 
CH^OSi. signal even after a large quantity of the shift reagent 
had been added.
Large LIS's were obtained with the C(CH^)^, CH, CH^N and NH 
groups. No observale LIS's were obtained with the (CH^)^Si groups. 
These observations show that the co-ordination centre is at the 
nitrogen atom where steric hindrance is minimum. There was no 
indication of any binding at the oxygen atoms of the 0-TMS groups. 
The signals of those protons distant from the binding site remained 
sharp throughout the experiment, whereas those nearer to the 
nitrogen atom gave broad and featureless resonances.
The S(+). salbutamol gave larger LIS than the R(-) isomer 
(figure 2:17B, page 98).
Optical purity determination:
Of the three solvents tested (CDC1_, CLD^ and CCI.), CCI,3 6 6 4 4
proved to be the most suitable, though benzene (d̂ ) gave sharper 
peaks. Figure 2:17A (page 98 ) shows the solvent effect on the 
differential shifts. Two chiral shift reagents - Pr(facam)^ and 
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Eu(facam)  ̂gave separation of the CH^OSi resonances. As with the
use of almost all chiral shift reagents, slight broadness of the
peaks at higher molar ratios was observed. Complete separation 
was not achieved. The base line technique, the chemical shift 
difference method and the peak height difference method were used 
for the analysis. Linear plots were obtained for all the methods 
indicating the suitability of the methods for the optical purity 
of salbutamol. The results are given in table 2:14 (page 94) and
in figures 2:18 and 2:19 ( p a g e g 9 9  & 100).
2.2.5 TETRAMISOLE
(2:11)
Tetramisole (6-phenyl-2,3,5 ,5-tetrahydroimidazo (2 ,1-b) thiazole) 
(2:11) is a broad-spectrum antihelmintic, active against neraatodes^^^ 
It was developed as%a direct result of metabolic investigations.on 
another compound , 2-acetylimino-3- 2Qhydroxy-2-(2-thienyl)ethyl] 
thiazoline ^Thiazothenol (2:12)) which was studied as an antihel­
mintic in sheep and poultry.
OH 
— CHgCH- 
^ s ̂ NCOCH,r~i
(2:12)
-102--
As synthesized, tetramisole is a racemic mixture. The anti­
helmintic activity is almost exclusively the property of the S(-) 
isomer - the S(-) isomer is twice as potent as the racemate and 
several times as active as the R(+) form. The toxicity of the 
two isomers is equal. Thus the relative safety of the S(-) isomer 
is about twice that of the racemate^^^'^^^.
Chemists at Janssen Laboratories established the absolute
configuration of the isomers by synthesis from the optically active
134intermediate phenylethylenediamines , and the American Cyanamid 
Company group resolved the racemic mixture^^^.
Tetramisole hydrochloride is readily soluble in water and is 
said to be effective by oral, subcutaneous, intramuscular and 
intraperitoneal administration.
Since the anthelmintic activity of tetramisole depends ex­
clusively on the S(-) isomer (levamisole), it is important that 
the optical purity be determined. In this work, a fast and simple 
method has been developed by the use of the chiral shift reagent 
Eu(facam)^ in CCl^/CDCl^ (5:2) using nmr. This involves integration 
of the *CH peaks for the (+) and (-) isomers (i.e. dexamisole and 
levamisole respectively). The peak height difference (6h) method 
was also employed for the analysis. The results are shown in table 
2:15 (page 105) and a plot of the peak height difference (ôh) versus 
the % optical purity is shown in figure 2:23 (page 111). The LIS's 
were also determined using Eu(fod)^, Pr(fod)^ and E u ( f a c a m ) T h e  
results for this determination are given in tables 2:15A - C 
(pages 103 and 104).
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Table 2:ISA. LIS of tetramisole using Eu(fod)^ in CCl^/CDCl^ (5:2)
[Tetramisole] = 0.24 M
MOLAR RATIO *CH Aromatic Aromatic




Tetramisole Ô Av 6 Av 6 . Av
0.0 5.35 0.0 7.22 0.0 7.22 0.0
0.062 6.08 0.73 7.75 0.53 7.25 0.03
0.099 6.54 1.19 8.00 0.78 7.30 0.08
0.183 7.53 2.18 8.85 1.63 7.38 0.16
0.342 9.78 4.43 10.05 2.83 7.54 0.32
Table 2:15B. LIS of tetramisole using Pr(fod)^ in CCl^/CDCl^ (5:2)
[Tetramisole] = 0.26 M
MOLAR RATIO Aromatic Aromatic




Tetramisole 6 Av 6 Av Ô Av
0.00 5.35 0 7.22 0.0 7.22 0.0
0.047 4.09 -1.26 6.37 -0.85 6.99 -0.23
0.106 + 5.05 -2.17 6.72 -0.50
0.189 + 3.35 -3.85 6.32 -0.90
+ *CH -resonance peak merged with other resonances.
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Table 2:16 Optical purity determination of tetramisole
Shift reagent: Eu(f a c a m ) M o l a r  ratio Reagent / Sample = 0.64
CCl^/CDCl^ (5:2); t Sample = 0.368 MSolvent:
Analytical peaks : *CH signals at Ô13.4 - 14.2 ppm










0.0 0.0 - -0.8
26.5 26.4 0.38 5.2
52.5 52.3 0.38 10.9
69.5 68.9 0.86 14.8
100.0 - - 21.8
t Mixture of dexamisole and levamisole.
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2.2.5.1 Results and Discussion 
Lanthanide induced shift:
With the Eu( f o d ) a l l  the shifts were downfield and with the 
Pr(fod)^ all shifts were upfield. The Pr(fod)^ induced shifts 
were larger than those of the Eu(fod)^. Pr(fod)^ gave much 
broader signals than those of Eu(fod)^. In both cases, the largest 
shift was given by the *CH signal indicating that the co-ordination 
occurs mainly at the imidazo-N =  C. Figure 2:21 (page 109 ) 
shows a plot of the LIS against the molar ratio of Eu(fod)^ to 
tetramisole.
In the nmr spectrum of tetramisole (figure 2:20A, page 108) 
only two resonance peaks could be assigned to particular groups of 
hydrogen, the aromatic protons at 67.25 and the *CH signal at 65.65 
ppm. The other protons displayed considerable signal overlap. 
Addition of few milligrams of a shift reagent revealed the presence 
of three single protons in the 3 - 6  ppm region, one of which has 
been identified as the *CH. Since there is no other single proton 
in the molecule other than the aromatic protons it was thought 
that the two protons close to the chiral centre might behave as two 
single non-equivalent protons, as is usually the case^^^. To 
ascertain this, decoupling experiments were performed using a 
LOO MHz instrument (Jeol 100). The decoupling technique showed 
that the triplet due to the *CH is in fact two doublets arising 
from coupling separately with the two protons adjacent to the *CH 
which are non-equivalent. The two non-equivalent methylene protons 
also couple separately with the *CH and with each other giving two 
doublets each which appear as two triplets due to signal overlap.
—107-
Using E u (facam)^ the 1 and d resonance peaks for the *CH group 
separated (figure 2:20B, page 108 . In view of the large coupling 
constant (Ca lOHz) and the triplet nature of the resonance, complete 
separation was obtained at high molar ratio (Ca 0.64). At this 
molar ratio, integration was possible though the resonances were 
broad.
At a molar ratio of 0.638, the resonance positions of the *CH 
were: dexamisole - 613.44 and levamisole 612.70 ppm. The results 
are given in table 2:15C (page 104) and a plot of the differential 
shift in figure 2:22 (page 110).
Optical Purity Determination:
The optical purity was determined using a molar ratio 
Eu(facam)_
Tetramisole
of 0.638. The solvent mixture (CDCl^/CCl^) was chosen
because CDCl^ is a better solvent but CCl^ gives larger differential 
shifts. Table 2:15 gives the results obtained for analysis of 
different mixtures of dexamisole and levamisole using integration and 
peak height difference methods. The methods are simple, and accurate. 
The main disadvantage is the low sensitivity of the *CH signal (only 
one proton). Because of this, optical purities above 7 0% could not 
be determined, since a large amount of the sample and Eu(facam)^ 
was required. In fact, provided enough sample and shift reagent 
(Eu(facam)^) are available, it is possible to determine optical 
purities up to 95%.
-108-
FIG. 2;20 A) Tetramisole (0-368M) in CCl^/ CDCl^ (5;2).
B) (A) in the presence of EuCfacam)^; Tetramisole / 
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The optical purity by the integration method was obtained by 
the use of the following formula :
I ' - Ioptical purity = — — x 100
where I' and I represent the integrals for the resonance paks, with 
I* being the isomer of larger quantity. A plot of the 6h against 
the optical purity is shown in figure 2:23 (page 111).
2.2.6 IBUPROFEN
CHj 
^  tH -C O O H
C H 3 '----'
(2:13)
Ibuprofen ^ 2-(4-isobutylphenyl)propanoic acid^ (2:13) is an
anti-inflAmmatory analgesic, and antipyretic compound used for the
137 138treatment of rheumatoid arthritis and other rheumatic diseases '
Ibuprofen consists of two enantiomorphs of equal anti-inflamm­
atory potency. However, the principal urinary metabolites (2:14,
1382:15) are dextrorotatory 
effected with (-)-1-phenylethylamine
The resolution of ibuprofen has been 
139




The two major human metabolites are inactive in anti-inflammatory
and analgesic tests, suggesting that ibuprofen is per se an active
138pharmacological agent . In humans, the (R)(-)-ibuprofen is
139epimerized to its optical antipode (S), (+)
Ibuprofen is a colourless, crystalline, stable solid of
melting point 75 - 77°C. It is slightly soluble in water but
readily soluble in most organic solvents. The sodium salt is
137 138readily soluble in water '
GLC methods have been utilized for the measurement of the in- 
139dividual enantiomers . The resolution involves the formation 
of diastereromeric amides with either (S)-(-)-o-methylbenzylamine 
or (R)-(+)-o-methylbenzylamine. Determination of the enantio­
meric purity by the above method is time consuming and tedious.
The use of nmr with chiral shift reagents appears to be simpler 
and faster.
In this work, the optical purity of ibuprofen has been deter­
mined by the direct application of the chiral shift reagent 
Eu(facam)^ in CCl^ at a molar ratio of 0.36, using the C-CH^ 
signals. The time involved in a single determination was less 
than 30 minutes after the preliminaries had been carried out.
The base line technique, the chemical shift difference and the 
peak height difference methods were employed for the analysis.
The optical purities of ibuprofen in 'Brufen' tablets and sus­
pension were also determined using the calibration curves obtained 
from the pure samples. The results for the optical purity
-114-
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Table 2:17B LIS of ibuprofen using Pr(fod)^ in CDCl^





Pr(fod)2 C C-CH^ -CH2" 2̂ & H3 & "5
Ibuprofen Ô Av Ô Av 6 Av 6 Av 6 Av
0.0 0.88 0.0 1.48 0.0 2.42 0.0 7.15 0.0 7.11 0.0
0.071 0.72 0.16 0.49 0.99 2.21 0.21 6.35 0.80 6.74 0.37
0.216 0.30 0.58 -1.60 3.08 1.72 0.70 4.66 2.49 6.02 1.09
0.309 0.00 0.88 -2.92 4.40 1.38 1.04 3.59 3.56 5.56 1.55
Table 2:17D LIS of ibuprofen using Pr(facam)2 in CDCl 3














Ibuprofen 6 Av Ô Av Ô Av 6 Av Ô Av
0.0 0.88 0.0 1.48 0.0 2.42 0.0 7.15 0.0 7.11 0.0
0.037 0.80 0.08 1.17 0.31 2.33 0.09 6.92 0.23 6.92 0.19
0.100 0.59 0.29 0.59 0.89 2.08 0.34 6.27 0.88 6.58 0.53
0.167 0.38 0.50 -0.15 1.63 1.85 0.57 5.67 1.48 5.32 0.79
0.227 0.18 0.70 -0.77 2.25 1.63 0.79 5.08 2.07 6.00 1.11
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Table 2:18 Optical purity determination of ibuprofen 
Solvent: CCI 4
Reagent: Eu(facam)^
*Molar Ratio: 0.366 ± 0.002 
[ibuprofen]= 0.23 M 
Analytical peaks: C-CH^














100.0 0.00 0.00 - 32.2
75.0 0.25 0.15 0.52 22.9
47.6 0.52 0.29 0.49 15.8
23.7 0.76 0.44 0.37 8.0
0.0 1.00 0.59 0.24 0.7
* Reagent / Ibuprofen
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determination are given in table 2:18 (page 117) and in figures 
2:25 and 2:27 (page 122). Results for the LIS and ALIS are also 
given in tables 2:17A - D (page 114) and in figures 2:24 and 2:25 
(pages 120 and^121).
2.2.6.1 Results and Discussion 
Lanthanide Induced Shift:
When Eu(fod)^ was used as the shift reagent, some of the groups 
shifted downfield while others shifted upfield. It is interesting 
to note that when the molecule (ibuprofen) is divided into two 






= U  . ^COOH
Right 
(Downfield shift)
groups of protons on the left hand side show upfield shifts and 
all those on the right hand side show downfield shifts. The down­
field shifts are larger than the upfield shifts since the site of 
co-ordination is on the right hand side of the molecule. Fig. 2:24A 
(page 120) shows the plots of the LIS against the molar ratio for 
the various groups of protons except for OR which could not be 
plotted on the same scale in view of the ..large shift.
Different results were obtained using the praseodymium analogue
-119-
Pr(fod)^ (figure 2:24B, page 120). All groups showed an upfield 
shift. The order of the LIS, as expected was: OH > CH > *CH > H
/ C H 3
and H > H and H > CH > CH > C . Larger induced shifts
^CH]
were obtained with Pr(fod)^ than with Eu( f o d ) H o w e v e r ,  broad­
ening occurred at much lower concentrations of Pr(fod)^ than with 
Eu(fod)^. The pattern of the graphs (fig. 2:24, page 120 ) was 
also interesting. The LIS obtained using Pr(fod)^ were linear, 
passing through the origin. Though those obtained with Eu(fod)^ 
were also linear, none passed through the origin. The pattern of 
the induced shifts obtained using the chiral shift reagents E u (facam)^ 
and Pr(facam)2 were similar to those of their non-chiral shift, 
reagent analogues.
At the concentrations of Pr(facam)^ employed there was no 
separation of the isomers. The experiment was discontinued at a 
molar ratio of 0.227 because the resonance peaks became broad and 
featureless. With the Eu(facam)differential shift was obtained. 
At the concentrations of Eu(facam)^ employed, the and the
aromatic protons and gave differential shifts for the (+) and 
(-) isomers. Fig. 2:25 (page 121 ) shows plots of the C-CH^ 
resonances versus the molar ratio, and the differential shift (AAv) 
versus the molar ratio. The (-) isomer gave larger LIS than the 
(+) isomer, though the LIS plots of the C-CH^ for the (-) and (+) 
isomers did not pass through the origin , the AAv plot passed 
through the origin .
Optical purity determination;
The C-CH^ signal gave sufficient separation for analytical
- 120- 
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purposes. Complete separation was not achieved in view of the
broadness of the peaks and integration was not feasible. Improved,
though not complete, separation was achieved by changing the solvent
from CDC1_ to CCI . (For the same concentration of substrate and 3 4 V
the same molar ratio, CCl^ induces larger differential shifts than
CDCl^ •)
All the new techniques - the base line, chemical shift and the 
peak height difference methods - gave a linear relationship when the 
separation (S), 6v and ôh were plotted against 1 - % OP/100 or % 
optical purity. The optical purity for the ibuprofen in the 
brufen tablets and suspension was found to be 0.0%.
2.2.7 NAPROXEN




was first developed as an anti-inflammatory agent by Harrison 
140et al. . It is 0.7, 5.5 and 11 times as active as indomethacin,
aspirin and phenylbutazone respectively, in inhibiting the carrageenin-
140-144induced inflammation of the rat paw . Most of its activity
140is due to the D(+) enantiomer . In humans, naproxen is excreted
-125-
as demethylated naproxen (28%) , glucuronide ester ( - 65%) and un­
changed naproxen (5 - 6%). The main route of excretion is via
. 144urine
Like ibuprofen, the enantiomeric purity of naproxen has been 
determined in this work by the use of Eu(facam)^ using the base 
line technique, the chemical shift difference and the peak height 
difference methods. Counting of squares under the analytical peaks 
(C-CH^) was also used for the optical purity determination. The 
results for the optical purity determinations are given in tables 
2:20A and B (page 1^1) and in figures 2:30 and 2:31 (pages 131 & 137) 
The results for the LIS are given in tables 2:19A - E and in figure. 
2:29 (page 135). Figure 2:28 (page 134) shows the nmr spectrum of' 
naproxen in CDCl^.
2.2.7.1 Results and Discussion 
Lanthanide Induced Shift (LIS) :
The pattern of the LIS was similar to that of ibuprofen. With 
E u (fod)2/ protons or group of protons on the right hand side of the 
molecule (see below) gave downfield shift and those on the left hand 
gave upfield shift.
H* ' H’ COOH
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Table 2:19B LIS of Naproxen using Pr(fod)^ in CDCl^











0.0 1.54 0.0 3.85 0.00 7.38 0.0 7.38 0.0
0.137 -0.39 1.93 3.51 0.34 6.00 1.38 5.56 1.82
0.232 -1.89 3.43 3.31 0.54 4.86 2.52 4.32 3.06
0.347 -3.32 4.86 2.99 0.86 3.60 3.78 2.81 4.57
0.474 -4.97 6.51 2.58 1.27 2.23 5.15 1.39 5.99
0.604 -6.50 8.04 2.00 1.85 1.00 6.38 - -■
*MOLAR RATIO: Pr(fod)^ / Naproxen
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Table 2:19D LIS of Naproxen using Pr(facam)^ in CDCl^










0.0 1.54 0.00 3.85 0.00 3.85 0.00
0.073 0.87 0.67 3.27 0.58 3.66 0.19
0.170 -0.14 1.68 + - 3.39 0.46
0.297 -1.30 2.84 + - 2.99 0.87
0.477 -2.86 4.40 + 2.40 1.45
0.591 -3.56 5.10 + - 1.89 1.96
+ broad and featureless
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Table 2:20 Optical purity determination of Naproxen
Solvent: CDCI3/CCI4 (3:4)
Reagent: Eu(facam) 3
*Molar ratio: 0.355 ± 0 .002
Analytical peaks: C-CH^
Resonance positions: 1 ___  52.30
d ___  51.80
- 2.60 ppm
- 2.10 ppm
Naproxen = 0. 29 M
A). By the new techniques
Optical OP, 








0.0 1.61 1.00 0.3 0.29
24.4 1.39 0.76 12.8 0.32
49.0 1.05 0.51 23.0 0.37
70.1 0.79 0.30 33.5 0.37
100.0 0.40 0.00 49.1 -






0.0 48 49 1.03
24.4 21 14 20.00
49.0 27 9 50.00
70.1 27 5 68.75
* Reagent / Naproxen
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At low molar ratios the downfield shifts were larger than the 
upfield shifts. At higher reagent concentrations the upfield 
shifts became larger than the downfield shifts. It appears that at 
low Eu(fod)3 concentration, the co-ordination is mostly at the OH. 
At higher reagent concentration co-ordination appears to be more 
favourable at the methoxy.
With the Pr(fod)3 all the shifts were upfield, with the C-CH^ 
group giving the largest shifts. The LIS results indicate that 
at molar ratios lower than 1.0 the co-ordination is mostly at the 
OH.
AAv:
The pattern of the LIS with Eu(facam)3 was slightly different 
from that of Eu(fod)3 in that the OCR3 gave the largest LIS even 
at low reagent concentrations. Differential shift was obtained for 
the C-C#3 group and the plots are shown in figure 2:29 (page 135). 
Though the OCH3 gave the largest LIS, no differential shift was 
obtained at the concentrations of the Eu(facam)3 employed. The OCR3 
resonance peak remained sharp almost throughout the experiment 
whereas the CH and C-CH^ became broad with increase in reagent con­
centration.
With the Pr(facam)3, no differential shift was obtained at the 
concentration of reagent used. Apart from the OCR3 resonance 
all other signals became broad, particularly those of C-CH^ and CH.
The differential shift obtained for the C-CH3 resonance peaks
-133-
using Eu(facam)^ and CDCl^ was not of sufficient magnitude to allow 
integration. It was considered that a change of solvent from CDCl^ 
to CCl^ might give a larger differential shift, to allow accurate 
integration. Unfortunately, solubility in CCl^ was very poor and a 
1:1 mixture of CDCl^/CCl^ had to be used. This gave larger diff­
erential shifts than CDCl^ alone (cf. tables 2:19C and E). However, 
complete separation was impossible since the OCH^ resonance peak 
coincided with the C-CH^ resonance peak. It was anticipated that 
at higher Eu(facam)^ / (±)-Naproxen molar ratios, the OC#^
resonance would separate from that of C-CH^ to allow the C-CH^ 
resonance peaks to be integrated, but this was not observed. A 
slight modification of the solvent mixture CDCl^/CCl^ (3:4) gave 
better separation (though not complete) and this was employed for the 
optical purity determination.
Optical purity determination:
Four analytical procedures were adopted: (1) the base line
technique, (ii) the chemical shift difference method (iii) the peak 
height difference method and (iv) counting of squares. With the 
new techniques a linear relationship was obtained when the various 
parameters were plotted against (1 - OP/100) for the base line 
technique, or optical purity for the chemical shift differenoeand 
the peak height difference methods. The linearity of the graphs 
(figures 2:30 and 2:31, page 136) is an indication of the accuracy 






























[ e u  ( f a c a m ^ n
I^Naproxen^


















































































CH C O O H
Ketoprofen 2-(3-benzoylphenyl)propanoic acid (2:17) is a non­
steroidal anti-inflammmatory agent with a comparable therapeutic 
efficacy with indomethacin when given in equal dosage^^^. It also 
has powerful analgesic and anti-bradykinin activities 150
The optical purity of ketoprofen has been determined from a 
study of its methyl ester (2:18) using Eu(facam)^ in CCl^. The base 
line technique and the chemical shift difference method were employed 
for the analysis.
2.2.8.1 Results and Discussion
Addition of a shift reagent to ketoprofen resulted in a broad 
signal for the C-CE^ group. In view of this, the methyl ester
derivative was used for the analysis, 
ester synthesis is given in Scheme 2:3
The equation for the methyl











Analytical peak: C-CH^ at 51.9 - 52.15 ppm.












Racemic (0.0) 1-0 9.0 5.0
20.0 0.80 7.2 6.2
45.0 0.55 4.8 7.8
70.0 0.30 2.7 9.5
78.0 0.22 1.9 9.9
* Reagent / Substrate
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FIG. 2.32 A) Ketoprofenmethyl ester ( 0-30M ) in CCl^
B) (A) in the presence of EuCfacam)^ at a molar


































FIG. 2:34 Optical purity determination of Ketoprofen
10.0 A) Base line technique
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It was anticipated that with (2:18), the COOCH^ signal, being a 
singlet, would be convenient for the analysis. Unfortunately, 
and surprisingly, it did not show any differential shift with Eu(facam) 
However, the C-CH^ signal gave a small differential shift (fig.
2:32, page 14c). As with most doublets, complete separation of the 
C-CH^ signal was not achieved. However, using scale expansion 
(lOOHz), the base line technique and the chemical shift difference 
method were used for the optical purity determination. Figure 2:33 
(page 141 ) shows the C-CH^ signals (in the presence of Eu(facam)^) 
at different scales.
Both the base line technique and the chemical shift difference 
method gave a linear relationship with the appropriate parameters. 





Fenoprofen ^ 2-(3-phenoxyphenyl)propanoic acid j (2:19)is a 
viscous oil b.p. / 0.11 = 168 - 171°C, with a pKa of 7.3. It is 
normally used in salt form, generally the calcium salt as the dihydrate
(C30B26Ca06'2H2°)'
Fenoprofen is a non-steroidal, anti-inflammatatory, analgesic
— 144—
145-148and antipyretic agent . It is safe and effective in the
treatment of rheumatoid arthritis. It has been found effective in
reducing uterine contractility without serious maternal or foetal
side-effects and shows promise as a clinically effective agent for
149the control of premature labour . Fenoprofen (1%) has a com­
parable efficacy with dexamethasone (0.1%) after topical application 
to rabbit eyes^^^.
In this work the optical purity of fenoprofen has been deter­
mined using the methyl ester derivative (2:20). The calcium salt 
was neither soluble in water nor in non polar organic solvents. 
Regeneration of the acid (fenoprofen) from the calcium salt proved 
difficult. It was therefore necessary to use the:methyl ester for 





CHCOOCH 3 + zCaClg + zHgO
Scheme 2:4
performed in CCl^ using Eu(facam)^ as the shift reagent. The 
COOCH^ signal was employed for the analysis.
2.2.9.1 Results and Discussion
The results for the ALIS are shown in figure 2:36 (page 148)
-145-
Table 2:22A LIS and ALIS of fenoprofen methyl ester in CDCl^
fFenoprofen-methyl esterj = 0.22M
MOLAR RATIO 
Eu(facam)
C00C#2 signal C-CH^ signal
1-isomer
FME
Ô Av 5 Av AAv Ô Av
0.0 3.62 0.0 3.62 0.0 0.0 1.47 0.0
0.276 3. 80 0.18 3. 80 0.18 0.0 1.66 0.19
0.669 4. 11 0.49 4. 11 0.49 0.01 1.82 0.35
0.858 4. 19 0.57 4. 18 0. 56 0.01 1.88 0.41
1.270 4. 56 0.94 4. 54 0.92 0.02 2.40 0.93
Table 2:22B LIS and ALIS of fenoprofen methyl ester
= 6 ° 6
if FME 0.171 M
MOLAR RATIO GOOCH 3 C-CH 3
Eu(facam)^ 1-isomer d-isomer 1-isomer d-isomer
FME Ô Av Ô Av AAv Ô Av Ô Av AAv
0.0 3.24 0.0 3 . 2 4 0.0 0.0 1.32 0.0 1.32 0.0 0.0
0.386 3.93 0.69 3.92 0.68 0.01 1.85 0.53 1.84 0.52 0.01
0.723 4.26 1.02 4.24 1.00 0.03 2.08 0.76 2.06 0.74 0.02
0.946 4.42 1.18 4.39 1.15 0.04 2.13 0.81 2.10 0.78 0.03
1.134 4.56 1.32 4.52 1.28 0.04 2.30 0.98 2.26 0.94 0.04
1.555 4.72 1.48 4.68 1.44 0.04 2.49 1.17 2.45 1.13 0.04
1.884 4.91 1.67 4.87 1.63 0.04 2.52 1.20 2.48 1.16 0.04
* FME = Fenoprofen methyl ester.
—146—
Table 2:22C ALIS of OCH^ and C-CH^ 6f fenoprofen methyl ester in 
CCI.













Table 2:23 Optical purity idetermination of fenoprofen using the
methyl ester derivative
Optical purity Peak height Chemical shift
1 - % OP Separation difference difference
(OP; %) 100 (S; mm) (1-d; mm) (6v; ppm)
0.0 1.00 18.0 0.4 0.06
20.0 0.80 14.5 2.4 0.09
55.0 0.45 8.6 5.7 0.14
80.0 0.20 4.6 8.2 0.17
Solvent: CClj4
Reagent : Eu(facam) 3
[FME] 0.215 M
*Molar Ratio: 0.919
Analytical peaks : COOCH^ at 65.2 -65. 3 ppm
* Reagent / FME
- 147 -
FIG. 2:35 A); Fenoprofenmethyl ester in CCl^
B); (A) in the presence of Eu(facam)^
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and in tables 2:22A - C. Of the three solvents chosen for the 
ALIS determination, CCl^ was the most suitable (fig. 2:36). At 
higher reagent concentration, solubility in CCl^ was a problem. 
However, at a molar ratio of 0.919 and a substrate concentration 
of 0.215 M the ALIS for the COOCH^ signals was large enough for 
the optical purity determination (fig. 2:35, page 147)-
All three techniques adopted for the optical purity deter­
mination proved suitable for the analysis. The results for the 
optical purity determination are given in table 2:23 (page 146) , and 
in figures 2:37 (page 149) and 2:38 (page 150). The linearity of 





Atropine dl-hyoscyamine (2:21) and 1-hyoscyamine (2:21) are
alkaloids obtained from various solanaceous plants such as Atropa
belladonna for atropine, and Hyoscyamus muticus or Duhoisia myo-
152poroides for hyoscyamine. They are also prepared synthetically
They are used medicinally as parasympatholytic agents, particularly 
153as antispasmodics
The optical purity of atropine/hyoscyamine has been determined
-152
Table 2:24A LIS for the and N-CH^ signals of atropine in
CDCl^ using Eu(fod)^ 
^ Atropine] = 0.174 M
MOLAR RATIO CH 0 N-CH_
Eu(fod)2 z j
Atropine Ô LIS 6 LIS
0.0 2.95 0.00 2.17 0.00
0.148 3.32 0.37 2.48 0.31
0.378 4.12 1.17 3.15 0.98
0.442 4.86 1.91 3.78 1.61
0.633 6.00 3.05 4.74 2.57
Table 2:24B ALIS for the COOCH^ signals of tropic acid methyl
ester• in CCl^ using Eu(facam)^
* [substrate] = 0.255 M
MOLAR RATIO Chemical shift (6-scale, ppm)
1-isomer d-isomer AAv(ppm)
0.0 3.64 3.64 0.00
0.246 1 4.70 4.70 0.00
0.440 5.50 5.50 0.00
0.565 5.93 5.90 0.03
0.728 6.37 6.29 0.08
0.876 6.70 6.58 0.12
1.010 7.07 6.89 0.18
Substrate - tropic acid methyl ester.
-153-
Table 2:24C ALIS for the CODCH^
ester in C_D_ using 6 6
[substrate]




MOLAR RATIO Chemical shift (6-scale, ppm) AAv
1-isomer d-isomer (ppm)
0.0 3.22 3.22 0.00
0.186 3.81 3.81 0.00
0.429 4.58 4.54 0.04
0.522 4.84 4.80 0.04
0.641 5.12 5.08 0.04
Table 2:25 Optical purity determination of atropine/hyoscyamine 














0.0 1.00 10 -0.2 0.144
18.2 0.82 8.2 7.5 0.160
46.3 0.54 5.3 19.5 0.195
63.8 0.36 3.6 26.5 0.215
100.0 0.00 0.0 42.8 -
Solvent: CCI,4
Reagent: Eu(facam)^
Substrate: tropic acid methyl ester
Molar ratio: Reagent / Substrate : 1.00
Analytical peaks: COOCH^ at 66.8 and 67.8
-154-
Table 2:26 Relationship between concentration of tropic acid methyl
ester (TAME) and separation (S)
Molar Ratio: Eu(facam)^ / T A  M E. = 1.00
Solvent: CClj4
Analytical peak : COOCH^ signal
Concentration of tropic acid methyl 







0.301 M 11.0 '
Table 2:27 Relationship between ’broadness' of the COOCH^ signal
of tropic acid methyl ester and molar ratio using
Eu(fod)^ in CCI•4
[t a m e ] = 0. 237 M
MOLAR RATIO Chemical shift Width of OCH^ Height of COOCH^
Ô (ppm) LIS
(ppm)
signal at h 
height (mm)
signal (cm)
0.0 3.64 0.00 0.90 9.41
0.145 4.20 0. 56 1.1 8.80
0.240 4.65 1.01 1.3 8.21
0.336 5.11 1.47 1.5 8.02
0.491 5.64 2.00 2.0 7.84
0.637 6.16 2.52 2.4 5.75
- 155 -
Schem e 2 :5
y C H
: 21)




N a C O C - C H - C H j O H
( 2 : 2 4 ]
I I HCI
CH3OOC— C H — CHzOH 
( 2 : 2  2 I  (Racemic.)
CH3OH
HCI H O O C - C H - C H j O H
( 2 : 2 5 )
CH;
Scheme 2:6






( 2 : 2 2 )  ( I- fo rm ]
-156-
by the use of Eu(facain)^ and tropic acid methyl ester (2:22) in 
CCl^. The atropine/hyoscyamine itself could not be used for the 
analysis because there was no suitable resonance. (2:22) was 
synthesised from atropine/hyoscyamine (schemes 5 and 6, page 155 ). 
The COOCH^ signal of (2:22) was employed for the analysis. Results 
for the LIS and ALIS are given in tables 2:24A - C (pages 152 & 153) 
and in figure 2:40 (page 158 ).
2.2.10.1 Results and Discussion
Synthesis of the 1-tropic acid methyl ester (2:22) from the 
1-hyoscyamine presented some difficulties (unlike that from atropine). 
Hydrolysis of the hyoscyamine with NaOH and extraction with chloro­
form when hot results in complete racémisation. It is believed
that the racémisation takes place at stage I of the synthetic route
154(scheme 2:5, page 155), and during extraction with chloroform 
To overcome this problem, acid hydrolysis is employed for hyoscy- 
amine, using ether extraction. When chloroform is used as extracting 
solvent the solution must be allowed to cool completely before the 
extraction. It has been reported^^^ that during the extraction of 
1-hyoscyamine, partial racémisation takes place. Complete racé­
misation takes place on treatment with alkali or heating in chloro­
form solution. Similar observations on the 1-tropic acid has been 
made since 1919^^^'^^^.
The problem of racémisation is critical and this approach of 
optical purity determination of atropine/hyoscyamine (through the 
formation of tropic acid methyl ester) is liable to false results 
if the right experimental conditions are not employed during synthesis
-157-
Q-O-O























































































































































































































































This clearly points out one of the dangers involved in the use of 
derivatives instead of the parent compound for optical purity 
determination.
Three solvents, CDC1_, and CCI . were considered for thej 6 6 4
analysis but only CCl^ was found suitable. Due to the incomplete 
separation of the COOCE^ peaks for the two isomers (1 and d), inte­
gration could not be used. The usual three techniques used for 
the analysis gave linear relationships with the appropriate parameter, 
A correlation coefficient greater than 0.98 was obtained in each 
case. The results are shown in figure 2:41 ( p a g e  159 ) and 2:42 
( p a g e  160 ) and in table 2:25 (page 153).
The relationship between the substrate concentration and the 
separation (S) is given in table 2:26 (page 154). A discussion on 
this is covered in the general discussion, page 42 . Table 2:26 
(page 154 ) shows the relationship between broadness of resonance 
peaks and the molar ratio. A discussion of this is also given in 







Dopa (3,4-Dihydroxyphenylalanine) (2:27) is an amino acid found
in seedlings, pods and beans of Vida faba L. (broad beans) , Stizo-
157lobium deeringianum L. (velvert beans) , Leguminosae . It is 
readily soluble in dilute acids and alkalis, and practically in­
soluble in absolute alcohol, ether, glacial acetic acid, petroleum 
ether and chloroform. Levodopa (L-Dopa) the naturally occurring 
amino acid is the immediate precursor of the synaptic neurotrans­
mitter substance dopamine. Unlike dopamine, Levodopa readily 
enters the central nervous system and has been used in the treatment 
of conditions such as Parkinson's disease, which may result from 
a depletion of dopamine in the brain. Levodopa has also been lused
to control the neurological symptoms of chronic manganese poisoning,
158which resemble those of parkinsonism
The enantiomeric ratio of Dopa has been determined using the 
(TMS)^-Dopa methyl ester (2:30) and Eu(facam)^ in CCl^. Dopa itself 
could not be used because of insolubility in common organic solvents. 
The methyl ester (2:28) was synthesised (scheme 2:7) but could not 
be used directly, because of insolubility. The (TMS)^ derivative 
of dopa itself was soluble in the common organic solvents but there 
was no suitable resonance peak for the analysis (scheme 2:7). In 
view of this, the (TMS)^-Dopa methyl ester (scheme 2:7) was pre­
pared and used for the analysis, employing the COOCH^ signal. The 
results for LIS and the optical purity determinations are shown in 
tables 2:28A - C and 2:29 (page 164) and in figures 2:44 (page 167) 
and 2: 45 (page.163) .
- 163 -
Scheme 2:7
H O  
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Table 2:28A LIS of the COOCH^ signal of (TMS)^-Dopa methyl ester 













Table 2:28B AAv of the COOCH^ signal 


















0.0 3.61 0.0 3.61 0.0 0.00
0.148 3.65 0.04 3.65 0.04 0.00
0.263 4.65 1.04 4.65 1.04 0.00
0.423 5.32 1.71 5.32 1.71 0.00
0.573 6.12 2.51 6.05 2.44 0.07
0.691 6.39 2.78 6.23 2.62 0.16
*The molar ratio calculation was based on the weight of Dopa- methyl 
ester (60 mg)
-165-
Table 2;28C AAv for the COOCH^ signal of (TMS)^-Dopa methyl ester




Substrate 6 Av 6 Av AAv
0.0 3.58 0.0 3.58 0.0 0.00
0.176 4.11 0.53 4.11 0.53 0.00
0.345 4.59 1.01 4.59 1.01 0.00
0.492 5.21 1.63 5.21 1.63 0.00
0.609 2.74 2.16 5.74 2.16 0.00
0.842 6.09 2.51 5.89 2.31 0. 20













0.0 1.00 6.8 0.1 0.19
20.0 0.80 4.8 5.2 0.23
51.8 0.48 3.0 12.3 0.28
80.0 0.20 1.3 18.8 0.34
100.0 0.0 0.0 23.4 -
Solvent CCI4
Reagent : E u (facam) 3
*Molar ratio: Reagent / Substrate = 0.842
Substrate : TMS-Dopa methyl ester
Analytical peaks : COOCH^ at 65 . 80 - 6.1 ppm
*The calculation of the molar ratio was based on the weight of the 
Dopa methyl ester (60 mg)
— 165—
2.2.11.1 Discussion
The two solvents, CDCl^ and CCl^, employed for the analysis 
proved equally suitable {cf. tables 2:28B and 2:28C, pages 164 
and 165 respectively). Thus, CCl^ was used for the optical purity 
determination. Linear graphs were obtained for all the three 
techniques employed for the optical purity determination (figures 
2 : 44 and 2 : 45) .
-167-












































































































2.3.1 QUININE AND QUINIDINE





methanol^ (2:31), ^^20^24^2^2 * ^̂ 2*̂  ̂ i-S the chief alkaloid of various
species of Cinchona (Ruhiaceae). It is a stereoisomer of quinidine 
and normally exists as the trihydrate. It is a highly active blood 
Schizonticide and suppresses the asexual cycle of development of the 
malaria parasite in the erythrocytes. It has some analgesic and
antipyretic properties and can also be used to induce labour and
• 158reduce night cramps
Quinidine (2:31) C. N^ N^O^ . 2H^0 is a dextrorotatory stereo-20 24 2 2 2
isomer of quinine. It is also obtained from the back of Cinchona 
species. It normally exists as the dihydrate. It is a cardiac de­
pressant, reducing the cardiac activity by directly depressing the 
excitability of the myocardium and prolonging the refractory period 
of cardiac muscle, thereby reducing the rate at which successive 
contractions take place. It also has anticholinergic actions^^^.
The diastereomeric ratio of quinine and quinidine (of prepared 
mixtures) has been determined without a shift reagent, and also by the
-170-
use of Pr(fod)^ a non-chiral lanthanide shift reagent.
2.3.1.1 Results and Discussion
The chemical shifts of quinine resonance signals in CDCl^ are 
slightly different from those of quinidine. The chemical shift diff­
erence for a particular group varies proportionally with a change in 
the diastereomeric ratio, without the use of a shift reagent (figures 
2:46, page 176 and 2:47A, page 177) . It was therefore possible to 
determine the diastereomeric ratio without the use of a shift reagent. 
However, the chemical shift difference (6v) was improved by the use of 
Pr(fod)^.
Three techniques - the chemical shift difference, the base line 
and the peak height difference methods - were employed for the dia-r - 
steromeric ratio determination.
Ci) The chemical shift difference method:
At low concentrations, quinine and quinidine have slightly 
different chemical shifts which are just noticeable if equal amounts 
of both quinine and quinidine are present (figure 2:46, page 176).
As the ratio (quinidine/quinine) increases:the chemical shift differ­
ence also increases linearly. The reverse, quinine/quinidine, vrs 
6v is shown in figure 2:47A, page 177 . Thus, the diastereomeric 
ratio can be determined accurately by the use of the chemical shift 
difference. The results for the experiments are given in tables 2:30A - 
C, page 172).
It was found that the chemical shifts of both quinine and quinidine 
decreased with increase in concentration (fig. 2:47B, page 177 ).
“171“
However, the chemical shift of quinidine is more concentration depend­
ent than those of quinine. Thus, when the amount of quinine was 
greater than that of quinidine in the mixture the chemical shift 
difference was very small. For the diastereomeric ratio determination 
in the absence of a shift reagent, the amount of quinidine must be 
greater than that of quinine in each case. In the presence of a 
shift reagent, the relative amounts are less important^since the 
chemical shift difference 15 almost doubled by addition of Pr(fod)^.
(ii) The base line technique:
An interesting result was obtained for the base line tech­
nique. The base line technique, which normally gives a linear plot,
gave a parabola with or without a shift reagent. The results are 
shown in figure 2:48 (page 178). However, when the log S was plotted 
against the ratio quinine/quinidine, a straight line was obtained 
(figure 2 :48B).
(iii) Peak height difference method:
Figure 2:49 shows the results for the peak height difference
method. A linear plot for the peak height difference versus the molar
ratio was obtained.
2.3.2 EPHEDRINE AND PSEUDOEPHEDRINE MIXTURE
A mixture of ephedrine and pseudo ephedrine could be determined
9readily by integration of the -CH peaks. The OCH signal for ephedrine 
is separated from that of the pseudo ephedrine by about 0.5 ppm.
Figure 2:50 (page 180) shows the nmr spectrum of a mixture of ephedrine 
and pseudo ephedrine. Though the other groups (e.g. NCH^ and the 
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Table 2:30C Effect of concentration on the chemical shift of quinine 









48.3 3.853 47.2 3.80
104.1 3.847 104.1 3.79
150.0 3.846 150.0 3.78
200.4 3.844 200.1 3.77
-175-
chemical shifts they are insufficiently large for accurate integration, 
The base line technique and the chemical shift difference method have 
been used successfully to determine the ratio of ephedrine to pseudo 
ephedrine in a mixture of the two by using the N-CH^ or the C-CH^ 
signals at a scale expansion. Using the N-CH^ signals, the region 
62.0 - 2.1 ppm was expanded on 100 Hz scale. For the C-CH^, the 
expansion was at 60.65 - 0.8 ppm.
Both the base line technique and the chemical shift difference 
gave a linear relationship when separation (S) or the chemical shift 
difference (6v) was plotted against the ratio of ephedrine to pseudo 
ephedrine. The results are given in table 2:31 and in figures 2:51 
and 2:52 (pages 131 and 182) .















0.3916 1.37 0.60 1.82
0.4763 2.03 0.72 1.70
0.8341 5.10 1.50 1.00
1.0230 6.95 1.76 0.78
- 176 -
FIG. 2:46 OCHg signals at different Quinine/Quinidine ratios
a) in the presence of PrCfod)^ (32mg.)
b) without shift reagent.












































































































































































































































FIG: 2:52 Diastereomeric ratio determination of Ephedrine/Pseudo 
ephedrine mixture by the application of chemical shift 





I. 00*80-60 -40- 2
Molar ratio: (Pseudo ephedrine/Ephedrine)







COO NH CO CH
(2:33)
The N'COCY^ signals for paracetamol (2:32) and benorylate (2:33)
resonate close together 52.07 and 52.10 ppm respectively in CDCl^/
DMSO(d-) (2:1) and therefore form suitable analytical peaks for 5
application of the base line technique to mixtures of two dissimilar 
molecules. A scale expansion at 100 Hz was used for the analysis.
A linear relationship was obtained when the separation (S) was 
plotted against the molar ratio ̂  Paracetamol / Benorylatej. The 
results are given in table 2:32 (page 185) and in figure 2:53 (page 
187). The results show that when the total weight of the mixture 
is known, it is possible to obtain the exact weight of each component 
in the mixture by using simultaneous equations. Due to the in­
complete separation of the N-COCi?^ peaks, accurate integration is not 
feasible and the application of the base line technique is useful.
2.4 2 CAFFEINE/CODEINE PHOSPHATE MIXTURE
The OCH^ and the N^-CH^ of codeine phosphate (2:35) and 
caffeine (2:34) respectively resonate close to each other 53.73 and 
53.85 respectively in DMSO(d^) but not so close as to permit the 
application of the base line technique (i.e. the molar ratios can 
be determined by direct integration). Addition of 3,4-dimethoxybenzoic 
acid (2:36) to the mixture of caffeine and codeine phosphate introduces 
two methoxy signals resonating at 53.78 and 53.80 ppm. This 













of the base line technique.
For the two results, two different curves were obtained when 
the separation (S) was plotted against the molar ratio, neither of 
which was linear. Figure 2:54 (page 188) shows the two graphs.
The results are given in table 2:33(page 185). The caffeine/3,4- 
dimethoxybenzoic acid graph gave a concave curve whereas the codeine 
phosphate/3,4-dimethoxybenzoic acid graphs was convex. This is 
due to the fact that the 3,4-dimethoxybenzoic acid and 
caffeine or the 3,4-dimethoxybenzoic acid and codeine phosphate 
have completely different structures unlike that of benorylate and
-185-













Table 2:33 The base line technique for codeine/caffeine mixtures using






Codeine phos. Separation 
(S; mm)
Int.standard Int.standard
1.165 32.0 1.134 28.3
1.003 28.4 1.002 23.6
0.660 22.8 0.538 16.9
0,5318 17.5 0.487 15.9
0.429 11.4 0.317 14.0
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paracetamol (see general discussion, page 43)
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Chiral lanthanide shift reagents offer a simple, fast and accurate 
means of optical purity determination. For partially resolved reso­
nance peaks the use of base line technique, chemical shift difference 
and peak height difference methods have been found suitable for 
optical purity or diastereomeric ratio determination. These tech­
niques involve the use of a calibration curve and they give a corre­
lation coefficient greater than 0.97.
The use of CLSR for optical purity determination is limited to 
compounds with few co-ordinating groups such as hydroxy and amino 
groups. For the optical purity of compounds with many such groups 
to be determined by the use of CLSR, derivatisation prior to the 
analysis is essential. Silylation has been found suitable in this 
respect.
2.5.1 Suggestions for further studies.
The base line technique is based on mathematical treatment (appendix) 
The equation derived involves two terms, a linear and quadratic. The 
quadratic term is significant, though the enantiomers and diastereo- 
mers studied gave linear relationship. Further investigation is needed 
to establish the relationship between structure and the technique.
To achieve base line separation of chromatograms, in HPLC or GLC^ 
alterations in the column conditions such as the flow rate, solvent 
systems, packing materials etc. is the normal procedure. This 
often makes analysis lengthy. Applicationcofithe base line technique 
may solve this problem.
2.6 EXPERIMENTAL
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Except where specified, all nmr spectra were recorded on a Perkin 
Elmer R12B instrument operating at 60 MHz and a probe temperature of 
37 ± l^C. TMS was used as the internal reference compound.
Infra red spectra were obtained on liquid films or as KCl discs 
(for solids).
Mass spectra were obtained on M.S. 12 instrument at 70 eV.
Elemental analysis were performed by the Butterworth Laboratories 
Ltd., Middlesex.
Melting points were recorded on a Gallenkamp melting point 
apparatus No. 889339.
NMR solvents, CCI , CDC1_, C_D_ and DMSO(d.) were dried over a 4 3 6 6 6
molecular sieve (4A).
Lanthanide shift reagents, Eu(fod)^, Pr(fod)^, Eu(facam)^ and 
Pr(facam)^ were purchased and stored over F^O^ in a desiccator.
Chemicals used were obtained from the following sources: 
iV, A7-Bis-(trimethylsilyl) trif luoroacetamide was purchased from 
Aldrich Chemical Co. Ltd. and stored in a refrigerator.
(±), (-) and (+)-ephédrines and pseudoephedrines as their hydro-
* *chlorides and sulphates , and (-) ephedrine base were supplied by 
Lake and Cruickshank Ltd., Manufacturing Chemists.
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*Propranolol (1, d and dl) as their hydrochlorides were supplied 
by ICI Ltd.
(±)-Salbutamol, R(-) salbutamol and S(+) salbutamol were 
supplied by Allen and Hanburys Ltd., London.
★Tetramisole -, Dexamisole- and Levamisole- hydrochlorides 
were supplied by Janssen Pharmaceutic, N.V. Beerse/Belgium.
Racemic ibuprofen, d-ibuprofen and 1-ibuprofen were supplied by 
the Boots Company Ltd., Nottingham.
(±)-Naproxen, (+) naproxen and (-) naproxen, supplied by the 
Syntex Laboratories Inc., California.
(±)-Ketoprofen and (+) ketoprofen, supplied by May and Baker.
(±)-Fenoprofen and (-) fenoprofen calcium salts, supplied by 
Lilly Research Centre Ltd.
Atropine and hyoscyamine were purchased from Sigma Chemical Co.
Ltd., Poole.
DL-Dopa and L-Dopa were purchased fron Aldrich Chemical Co. Ltd., 
Gillingham.
Quinine SH^O and Quinidine ZH^O, caffeine, codeine phosphate and 
paracetamol were purchased from Evans Medical Ltd., Bristol.
* The bases were obtained from their proton salts by dissolving them in
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water, basifying with NaOH (20%) and extracting with ether or 
chloroform. The organic layer was dried over anhydrous sodium 
sulphate and then removed. The residue was dried in vacuo at a 
temperature not exceeding 50°C.
2.5.1 Determination of LIS :
A solution (Ca 0.2 - 0.4 M) of the sample in the appropriate 
solvent (0.7 ml) was prepared. The nmr spectrum was recorded. 
Eu(fod)^ and Pr(fod)^ in 10 - 20 mg quantities were added increment­
ally and the spectrum recorded again after reach addition. The LIS 
of the appropriate signals were measured and plotted against the 
molar ratio ( Reagent / Substrate ).
2.5.2 Determination of Differential Shift (AAv)
The above procedure (section 2.6.1) was repeated with the racemic 
material and employing the chiral shift reagents Eu(facam)^ and Pr(facam)^
2.6.3 Optical purity determination
2.6.3.1 For ephedrine, pseudo ephedrine, propranolol, tetramisole, 
ibuprofen, naproxen, fenoprofen and atropine/hyoscyamine.
Different quantities of the 1 and d isomers^ (or the racemic
and any of the pure isomers available) were mixed to give different
optical purities but approximately the same final concentration. Each
*
mixture was dissolved in the appropriate solvent (0.7 ml) and a
* Details of solvents, CLSRs and molar ratios are given in the appropriate 
tables
+ For propranolol, the N-acetyl derivative (2:7) was employed. For 
fenoprofen, the methyl ester derivative (2:20) was used. For 
atropine/hyoscyamine, tropic acid methyl ester (2:22) was used.
(See page 194 for the synthesis of the various derivatives.)
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*
quantity of the CLSR added to yield the appropriate *molar ratio 
( :;Eu (facam) 2 / total substrate ). The nmr spectra of the various
resulting solutions were recorded under the same instrumental conditions, 
The base line (S), the chemical shift difference (6v) and the peak 
height difference (5h) of the analytical signals were measured and 
plotted against the appropriate parameter. Where suitable, integrals 
of the analytical signals were recorded.
2.6.3.2 Salbutamol
Various quantities of R (-)salbutamol and S (+)salbutamol were 
mixed to obtain different enantiomeric mixtures. In each case the 
total weight of salbutamol taken was 57 - 61 mg. BSTFA (0.4 ml) was 
added to each mixture and the temperature then maintained at 130°C 
for 10 - 15 mins. The excess BSTFA was removed in vacuo abd the product 
treated with an amount of Eu(facam)^ which would give a molar ratio 
of 1.602 when benzene (d̂ ) was used or 1.19 when carbon tetrachloride 
was used as the solvent. The nmr spectra of all solutions were re­
corded and the base line technique, chemical shift difference cuid 
peak height difference methods used for the analysis employing the 
0C#2 signal at 54.6 - 5.4 ppm.
2.6.3.3 Ketoprofen
Different quantities of racemic ketoprofen and the d-isomer 
were methylated as described (page 19^ . The methyl ester mixtures 
were dissolved in CCl^ to give a total concentration of about 0.182 M 
in each case. A calculated amount of Eutfacam)^ was added to each 
mixture in CCl^ to give a molar ratio (Eu(facara)^/ketoprofen methyl 
ester) of 0.406. The nmr spectrum of each solution was recorded.
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The C-CH^ signal at 61.9 - 62.15 ppm was expanded (scale expansion
at 100 Hz) and the base line technique and the chemical shift 
difference method applied for the analysis.
2.6.3.4 Dopa
Various quantities of the L- and DL-Dopa methyl ester were mixed 
together to obtain different enantiomeric ratios. These were used 
to prepare the silyl derivative of dopa methyl ester (page 197).
The products were dissolved in CCl^. A calculated amount of 
EuXfacam)^ was added to each mixture to give a molar ratio of 0.842. 
[rhe calculation of the molar ratio was based on the weight (0.06Q) 
of the dopa methyl esterjj . The nmr spectra of the various mixtures 
were recorded. The COOCH^ resonance peaks at 65.80 - 6.1 ppm were 
used for the analysis employing the base line technique, chemical 
shift difference and peak height difference methods.
2.6.4 Synthesis of Derivatives
2.6.3.1 W-acetylpropranolol
Freshly distilled acetic anhydride (0.3 mis) was added to 
propranolol (0.85 g) dissolved in dried tetrahydrofuran (5 ml).
The mixture was stirred overnight. The solvent was removed in 
vacuo and the residue dissolved in chloroform (20 ml.). The organic 
layer was washed with N/10 HCl (10ml), and then with N/10 NaOH 
(10 ml). The chloroform was removed and the residue (an oil) crys­
tallized from petroleum ether (b.p. 40 - 60°C)/ether (1:3) mixture. 
The sample was dried, and then recrystallized from ether yielding
N-acetylpropranolol (0.45/g; 45.6%), m.p. 103.9 - 104.2^0.
1690
V : 2950,\ 1603, 1470, 1385 cm . max \
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Found: C, 70.8; H, 7.8; N, 4-8%.
C H  NO requires: C, 71.7; H, 7.6; N, 4.7%.Lo zj j
The nmr spectrum is shown in figure 2:12 (page 86 ).
2.6.4.2 (O-TMS)  ̂ Salbutamol.
Salbutamol (0.06g) was treated with excess of BSTFA (ca 0.4 ml) 
in a stoppered flask (5 ml) and the temperature maintained at 130^0 
for 10 - 15 mins. The excess BSTFA was removed in vacuo at about 
50^0. The oil remaining was distilled. The fraction b.p. 140 - 
142^0/0.8 mm Hg. was collected. ’̂max* 3,000, 1620, 1508, 1262,
860 cm"^. M/e (%); 457 (2), 442 (5.7), 370 (34), 368 (98),
192 (3.4), 148 (18), 147 (100).
Found: C, 57.9; H, 9.9; N, 3.7; Si, 18.0%.
^22^45^^3^^3 esquires C , 58.3; H, 9.9; N, 3.1; Si, 18.5%.
The nmr spectrum is shown in figure 2:16 (page 97 ).
2.6.4.3 Ketoprofen methyl ester
Ketoprofen (0.05 g) was dissolved in methanol (ca 20 ml) con­
taining conc. HCl (ca 1 ml). The mixture was refluxed for 1 hr.
The excess methanol was removed in vacuo and the liquid residue, 
Ketoprofen methyl ester, used for the analysis, 1740, 1690,
1590, 1500 cm
The nmr spectrum is shown in figure 2:32A (page 140).
2.6.4.4 Fenoprofen methyl ester
The calcium salt (0.5 g) was dissolved in hot methanol (ca 40 ml), 
and the mixture acidified with conc. HCl (ca 1 ml). The solution 
was concentrated in vacuo, and the residue, fenoprofen methyl ester.
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as a liquid, was used for the analysis. v : 1735, 1590, 1500,max
1250 cm ^.
The nmr spectrum is given in figure 2:35A (page 147).
2.6.4.5 Tropic acid methyl ester
2.6.4.5.1 dl-tropic acid methyl ester
*Atropine (0.6 g) was dissolved in ethanolic sodium hydroxide 
solution (20%, 40 ml) and refluxed for 1 hr. The reaction mixture 
was allowed to cool and extracted with chloroform (3 x 20 ml).
The organic layer was discarded after washing with water (3 x 4 ml). 
The bulked aqueous layer was acidified with conc. HCl (1 ml) and 
extracted with chloroform (3 x 20 ml). The combined chloroform 
extract was dried (Na^SO^) and removed in vacuo. The residue was 
dissolved in methanol (30 ml) containing conc. HCl (1 ml) and the 
mixture refluxed for about 1 hr. The methanol was removed in vacuo. 
The dl-tropic acid methyl ester (0.23 g, 62.6%), m.p. 35°C crys­
tallized as fine needles from petroleum ether (b.p. 60 - 80°C), m.p.
37° - 38°C. (lit.^^^ 36.5 - 37.5°C). v : 3200 - 3600, 2960,max
1750, 1500 cm ^.
The nmr spectrum is shown in figure 2:39 (page 157 ) . Addition of
EuCEacam)^ at a molar ratio (Eu (facam^-^/^l-tropic acid methyl ester)
of 1.00 gave two singlets at 66.8 and 67.8 ppm in CCI (3H, 2S,4
COOCH ).
2.6.4.5.2 1-tropic acid methyl ester
1-hyoscyamine (0.5 g) was refluxed in N/10 KCl (30 ml) for 2 hr
* Hyoscyamine gives similar results (see page 155) .
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The reaction product was allowed to cool and extracted with ether
(60 ml). The ether was dried (Na^SO^) and removed In vacuo. The
residue was dissolved in methanol (30 ml) containing conc. HCl (1 ml)
and the mixture refluxed for about 1 hr. The methanol was removed
in vacuo. The 1-tropic acid methyl ester (0.18 g, 59.1%), m.p. 3.6-
37.5°C. V : 3200 - 3600, 2960, 1750, 1500 cm ^. Addition of max
Eu(facam)2 at a molar ratio of 1.00 (Eu(facam)^7(“tropic acid methyl 
ester) gave a singlet at 67.8 ppm in CCl^ (3H, S, COOCH^).
2.6.4.6 Dopa methyl ester
Dopa (1.0 g) was dissolved in methanol (ca 40 ml) containing conc. 
HCl (1 ml). The mixture was refluxed for 1 hr and the methanol removed 
in vacuo. The product was crystallised from aqueous ethanol yielding 
dopa methyl ester as, (0.56 g, 52.5%), m.p. 103 - 105°C. 3200 -
3600, 1745, 1490 cm~^. 6(CC1 ): 2.65 - 3.00 (2H, m, CH^), 3.40 - 3.75
(IH, m, CH), 3.70 (3H, S, COOCH ), 6.72 (3H, S, Ar-H).
Found: C, 57.5; H, 5.9; N, 6.5%.
C^gH^^NO^ requires: C, 56.9; H, 6.2; N, 6.6%.
2.6.4.7 (TMS)2-Dopa methyl ester
Dopa methyl ester (ca 60 mg) and BSTFA (0.5 ml) were heated at 
160°C for 10 mins. The excess BSTFA and the trifluoroacetamide 
were removed. The product was used immediately for the enantiomeric 
ratio analysis.
6(CC1 ); 0.02 (9H, S, Si(CH )^, 0.30 (18H, S, 2X-Si(CH^)^, 2.60 - 4 3 3 3 3
2.95 (2H, m, -CE^), 3.30 - 3.69 (IH, m, CE), 3.62 (3H, S, COOCE ), 
6.64 (3H, S, Ar-E).
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2.6.5 Determination of diastereomeric ratios of Quinine/Quinidine 
and Ephedrine/pseudo-ephedrine.
Different quantities of quinidine and quinine or ephedrine and
pseudo-ephedrine were mixed together in CDCl or C D  respectively3 6 6
to obtain different diastereomeric ratios but the same total concen­
tration (see tables 2:30A, page 172 and 2:31,page 175). The nmr 
spectrum of each mixture was recorded and the chemical shift 
difference (6v), the separation (S) and the peak height difference 
(6b) of the analytical peaks (OCE^ for quinine/quinidine and N-CE^ 
or C-CE^ for ephedrine/pseudo-ephedrine) measured. The values 
obtained were plotted against the appropriate parameters (see 
figures 2:47 to 2:51, pages 177&181). For the quinine and quinidine 
mixture, Pr^fod)^ (32 mg) was added to each mixture and the procedure 
repeated (see table 2:30B, p a g e  173).
2.6.6 Base line technique for dissimilar molecules
2.6.6.1 Benorylate/paracetamol mixture
Different amounts of benorylate and paracetamol were dissolved 
in CDCl^/DMSO(d^) (2:1, 0.7 ml) to give different molar ratios (see
table 2:32, page 135 ). The nmr spectrum of each mixture was re­
corded. The analytical region, 62.0 - 2.1 ppm, due to the N-CE^ 
peaks of the two compounds were expanded on a lOO Hz scale and the 
separation (S) recorded and plotted against the molar ratio (para­
cetamol/benorylate) .
2.6.6.2 Caffeine/codeine phosphate mixture
Different quantities of caffeine, dimethoxybenzoic acid (DM3A) 
and codeine phosphate were dissolved.in DMSO(d^); (O .7 ml) to give
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different caffeine/DMBA and codeine phosphate/DMBA - molar ratios 
(see table 2:33, page 135). The nmr spectrum of each mixture was 
recorded. The analytical region , 63.7 - 3.9 ppm, due to the 
OCH^ of codeine phosphate, N^-CH^ of caffeine and 2{0CH.^) of DMBA, 
was expanded on a 100 Hz scale. The separation (S) due to 
caffeine/DMBA at 63.85 - 3.80 ppm and that due to codeine phosphate/ 
DMBA at 63.73 - 3.78 ppm were measured and plotted against the molar 
ratios.
PART 3
3. NMR QUANTITATr/E ANALYSIS OF PHARMACEUTICALS
3.1 GENERAL DISCUSSION
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Many pharmaceutical preparations have been assayed successfully 
by nmr. The method involves the addition of an internal standard 
to the sample and subsequent extraction with a solvent. The 
appropriate analytical peaks are integrated after the nmr spectrum 
has been recorded. The weight (Ŵ ) of the sample is then calculated 
from the following general formula:
^T'^T'^S
where is the nmr equivalent weight of the sample
Eg is the nmr equivalent weight of the standard
is the integral of the sample analytical peak(s)
Ig is the integral of the standard analytical peak(s)
Wg is the weight of the standard taken.
Except where indicated this was the method of calculation adopted for 
all assays discussed.
The internal standards employed and their equivalent weights 
are listed in table 3:1A (page 202)- In some of the assays, the 
pure samples of the active ingredients were used as internal standards 
for two reasons:
(1) where no available internal standard was suitable and
(2) to demonstrate the usefulness of the chemical itself as internal
standard.
In addition to the nmr method, the official methods of analysis
were also performed for comparison. A summary of the results are
given in table 3:IB (page 202). As seen in this table, the nmr and
-201-
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the official methods have comparable accuracy in most cases. One 
clear exception was "Benoral" suspension where the average percent 
labelled strength (110.4) was high as compared with that of the 
other method (99.5).
The nmr method had four advantages: simplicity, speed, sample
size and specificity.
Simplicity: In most cases the nmr method was simpler than the
official methods, excépt those cases where a UV analysis was possible.
Speed: NMR offers a rapid method of analysis. The maximum duration
for a single analysis was 40 minutes including sample preparation.
In most cases this is only a fraction of the time required by
official methods. In this respect, nmr is comparable to UV analysis,
It has a clear advantage over the other official methods.
Sample size: The quantity of sample required for nmr analysis is
18small. Concentrations of about 10% are generally required for 
good nmr spectra, but since the volume of solvent required is small, 
this concentration is obtained with a small amount of the sample. 
Specificity: The nmr spectrum often reveals the presence of any
impurities in significant concentration and any changes in the 
structure of the compound under investigation by the appearance of 
extra resonance peaks or disappearance of a known peak. It is often 
possible to identify the impurities, and in this respect, nmr 
quantitative analysis is a useful quality control method.
The nmr method was less precise than the existing methods (see 
table 3:IB, page 202). A higher coefficient of variation was ob­
tained in all the analysis compared with the existing methods. Since
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most of the published work on nmr quantitative analysis claim low
49standard deviations , the high value obtained in this work might 
be due to instrumental factors.
NMR has long been noted as unsuitable for assay of low dosage 
2pharmaceuticals . The assays of 'Codis' (section 3.4.2, page 264), 
'Cafadol' (section 3.4.3, page 269) and 'Parahypon' (section 3.4.4 , 
page 269) clearly demonstrate the use of nmr for low dosage drugs. 
Addition of a known weight of the analar drug to the analytical sample 
increases the nmr signal sensitivity of the sample and therefore affords 
measurable integrals. The codeine phosphate content of 'Codis' is 
8 mg per tablet. The nmr analysis gave 94.7% labelled strength which 
compared favourably with the results obtained by the official method 
(94.5%). Satisfactory results were also obtained for the caffeine 
citrate and caffeine content in 'Cafadol' and 'Parahypon' respectively.*
One problem with nmr quantitative analysis is the possible 
inteference from excipient materials (see section 1.2, page 16).
In this work, there was only one clear case where excipient resonance 
peaks interfered with the analytical peaks which precluded the nmr 
assay (see section 3.4.5, page 273).
The success of nmr quantitative analysis depends critically on 
the method of measurement of the analytical signals. When peak 
height method was compared with integration, the former method was 
found less accurate than the latter. An error as high as 10.74% 
was obtained for peak height measurement and 0.82% for integration 
in the assay of 'Panadol' (section 3.3.1, page 217). In the same
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analysis, peak height measurement was found less precise (coeff. 
var. 5.21%) than integration (coeff. var. 2.47%). Similar results 
were obtained for gentamicin analysis (see table 3:3, p a g e  210).
3.2 GENTAMICIN C
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Gentamicin C(3:l) is a broad spectrum, basic deoxystreptamine con­
taining antibiotic produced by Micromonospora species^^^'^^^. It 
is a mixture of three major components designated and
161,164
Analysis indicates that forms about 35 - 5 0 % , forms about
30 - 45% and C, forms about 10 - 20%.of the total Gentamicins la
They have, however, almost the same biological activity^^^'^^^. 
Separation and differentiation of this gentamicin complex has been 
effected by chromatographic techniques^^^ 166^ Assay procedures 
for the determination of the total Gentamicins and the individual 
components are based on microbiological assay and paper chromato­
graphic techniques^^^'^^^'^^^. NMR has also been adopted as a limit
















Recent-ly a comparison of the three methods - microbiological, 
chromatographic and nmr - has shown that nmr is the most useful
method for evaluating the composition of gentamicin sulphate^^^. The 
standard erros obtained for gentamicin by the three methods were 
± 5.61, ±5.32 and ±1.38 respectively.
The nmr method^^® is a limit test based on the#-methyl ratio 
of the^peak at 62.75 to the peak at 2.95 (see table 3:2). -Therefore 
rt does not give the actual amount of gentamicin present. In this 
report an nmr method of assay is described for the total gentamicins, 
as well as the individual components (C^, and C^^). It is based 
on integration of the signals at 61.25 - 1.35, 62.75 and 62.95 (table 
3:2), using maleic acid as internal standard and D^O as solvent.
Table 3:2 Assignment of the analytical peaks
Position of signal 





Integration of the signal at 62.95 gives an area indicative of
the total gentamicins since the resonance is due to the N-CH^ of the 
Garosamine moiety which is common to all three components. Similarly, 
the signal at 61.35 is due to the C-CH^ of the Garosamine ring and
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hence represents the total gentamicins. Integration of the latter 
signal is, however, not feasible because of signal overlap (figure 
3:1, page 207). The signal at 61.25 represents both and (table 
3:2), and therefore total integration of the two signals at 61.25 
and 1.35 represents the total gentamicins plus and . Integration 
of the signal at 62.75 represents C^.
3.2.1 Assay of total gentamicins
The assay procedure was applied to three separate gentamicin 
samples. Two of the samples were gentamicin sulphate powder and 
the third was gentamicin injection. Ten determinations were made 
on each sample. The N-CH^ signal at 62.95 and the maleic acid 
olefinic proton signal at 66.35 were utilised for the analysis. 
Peak height measurement was employed on one sample for comparison. 
A summary of the results is shown in table 3:3 (page 210).
The equivalent weight of the total gentamicins (Ê ) was obtained 
as shown below:
= Total M. Wt. of the gentamicins_________________
Total no. of protons giving the signal at 62.95
Î i2Z_+..i63_±_449 ^ 154.33
The ratios of the individual components were approximated to be 
334 % each.
The results obtained from the peak height measurement clearly 
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3.2.2 Assay of the individual components of gentamicin
The calculation for the individual gentamicins was based on 
the following:
Table 3:4











signal E - signal A 
D - B
A - D or 2A - E 
159 X B X W^
= D
E X I s s
154.33 X (D-B) X W
E X I s s
Wt. of Cla
149.67 X (2A-E) x W^
E X I s s
where 159, 154.33 and 149.67 are the equivalent weights of C^, 
and respectively.
The integrals of signals A, B and E were recorded and individual 
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The results for the average % w/w obtained for the total gen­
tamicins was below the labelled strength. To investigate this, known 
quantities of the individual gentamicins were mixed together and 
assayed. The results are expressed in table 3:5 (page 215).
The results obtained for the individual components were incon­
sistent. Moreover they were contrary to that expected (page 205). 
When the spectrum of gentamicin alone was recorded, it was observed 
that signals A (62.95) and B (62.75) were not equal both in height 
and in area (integral). The two signals should be equal in every 
respect for gentamicin C^. This may account for the low results 
obtained for C^.
From a consideration of structure twice the integral for signal 
A should equal the integral for signal E (61.35 - 1.25) for pure 
and pure , but, again, this was not observed. Rather 2A > E.
This may account for the low value of and high value of
It is considered that these results may reflect interference from
other minor components in the gentamicin mixture^^^.
In view of these findings it was thought reasonable to in­
vestigate whether there was a constant ratio between signals A and
B, and that of 2A and E, in different experiments using C and C ,
1
and a mixture of the two. The results are shown in table 3:7, page 
216. It is clear that there is no constant ratio between signals 
A and B , and between signals E and A. This might be due to 
instrumental factors. Since no constant ratio was obtained in 
either case, the method is not applicable to the assay of individual
“214-
components of gentamicin C.
3.2,3 CONCLUSION
Though the indivdüal components of gentamicin C could not be 
assayed successfully, the method is not without merit. The total 
gentamicins may be assayed successfully by this method. Under proper 
conditions of integration and measurement of integrals, the method 
gives 100.5% accuracy with 4.4% variation. The assay can be com­
pleted in about 30 mins. The biological assay method takes up to 18
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(mg) Ratio: Ratio: f- A
S 36.0 0.825 0.673
28.5 0.823 0.676
=1 46.5 0.802 0.695
25.4 0.777 0.665
=1 19.1 0.806 0.677
=1 29.3 0.851 0.769
52.7 0.821









'Panadol' is a tablet preparation with paracetamol (500 mg) as 
the active ingredient. It is used as an analgesic and antipyretic.
Paracetamol (2:32) shows a sharp singlet at 62.01 ppm due to the 
NCOCH^ group. On the basis of the paracetamol spectrum and the avail­
ability of material, 3,4-dimethoxybenzoic acid was selected as the 
internal standard. Paracetamol and 3,4-dimethoxybenzoic acid were 
only sparingly soluble in CDCl^ but readily soluble after addition
NHCOCH3
^2:32^
of a few drops of DMSO(d ). A mixture of CDCl /DMSO(d.) (1:3) was5 3 5
therefore used for the analysis. For comparison, both integration 
and peak height were employed for the measurement of the resonance 
peaks. The results are given in table 3:8, page 218.
The official^^^ method of assay for paracetamol tablets was 
followed and the results compared with those obtained for the nmr 
method. The results are given in table 3:9, page 219 . The official
method involves extraction of paracetamol into NaOH followed by 
measurement of the extinction of the resulting solution at 257 nm.
Using integration, the average weight of paracetamol obtained per 
tablet (504.1 mg) compares favourably with the result obtained by 
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method the average weight of paracetamol obtained per tablet was 
44.5 mg, with a high coefficient of variation (5.2%). Integration 
is therefore the method of choice for the parcetamol determination.
The average time taken for a single determination (including 
measurement of integrals and calculation) was about 10 mins after 
sample preparation.
3.3.2 'BRUFEN' TABLETS AND SUSPENSION
'Brufen' tablets (400 mg) and suspension (100 mg/5ml) have been 
assayed successfully by the use of nmr and employing 3-acetobenzyn 
thiophene as an internal standard. The results are given in tables 
3:10 and 3:11, pages 222 and 223).
3-Acetobenzthiophene was used to demonstrate the use of an 
internal standard whose analytical resonance peak inteferes with 
that of the sample. The CiCH^)^ resonance of ibuprofen was used 
as the sample analytical peak. Since the standard peak came close 
to the CH^ peak of ibuprofen (figure 3:2, page 221) it was necessary 
to integrate both and to correct for the contribution of the standard. 
Thus, the integral for the standard peak (Î ) was given by
BI = A - —s 3
where 'A' is the total integral for the standard and the CH^ peaks 
and 'B' is the integral for the C{CH^)^ peaks.
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UV method (page 285) for comparison with the nmr method. The 
results are given in tables 3:12 and 3:13, pages 224 and 225.
The results for both the suspension and tablet nmr assays compare 
favourably with those obtained by the UV method. However, a higher 
coefficient of variation was obtained for the nmr method.
3.3.3 EPHEDRINE HYDROCHLORIDE POWDER
The possibility of using nmr for the assay of Ephedrine HCl was 
investigated. With- D^O as the solvent, maleic acid as the internal 
standard and the aromatic resonance as the sample analytical peak, 
a very precise, accurate and fast analysis was obtained. The results 
are given in table 3:14. The method was compared with the official 
assay method^^^. It was found that the nmr method was slightly 
inferior to the official method (non-aqueous titration) with regard 
to accuracy and precision. The standard deviation for the nmr method 
for eleven results was 1.04 whereas the standard deviation for the 
non-aqueous titration method for only four results was 0.03. However, 
the.nmr method was faster than the non-aqueous titration. Another 
advantage of the nmr method was that it required less material for 
the analysis than the titration. The results for the non-aqueous 
titration are given in table 3:15, page 228.
3.3.4 PSEUDO-EPHEDRINE HYDROCHLORIDE POWDER
As with ephedrine hydrochloride, pseudo-ephedrine hydrochloride 
gives a singlet for the aromatic protons in D^O. Using maleic acid 
as the internal standard, results similar but of higher standard 
deviation, to that of ephedrine hydrochloride were obtained. The 
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Orudis contains ketoprofen, 50 mg per capsule. The ketoprofen 
content of "Orudis" has been determined using 3-acetobenzthiophene 
as the internal standard. The C-CH^ signal of ketoprofen was used 
as the sample analytical peak. The results are given in table 3:17, 
page 232 •
Some resonance peaks due to the excipients appeared in the spectrum 
close to the sample analytical peak (figure 3:3, page .230).However they 
did not interfere with the analysis. This is clear from the results 
obtained which compare favourably with the results obtained by a 
UV method (shown in table 3:18, page 233).
3.3.6 'INDERAL'
Inderal is a tablet preparation containing propranolol hydro­
chloride (80 mg per tablet) as the active ingredient.
The propranolol hydrochloride content of 'Inderal' tablets has 
been determined successfully by nmr using pure propranolol hydro­
chloride as internal standard. The experiment illustrates the fact 
that an internal standard based on the pure form of the test sample 
can be as good as the other internal standards. Two determinations 
were carried out at a time. In one case the nmr spectrum of the
sample alone was recorded, in the other case both the sample and the pure
propranolol hydrochloride were dissolved in the same quantity of 
solvent and the spectrum recorded. The aromatic peaks were used as the
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The results were compared with those obtained by the official^^^
method (table 3:20, page 237). The official method is a UV method
of assay which involves extraction of the propranolol hydrochloride.
1%into methanol and measurement of the extinction at 290 nm, E,1cm
= 210 at 290 nm .
The nmr and official methods gave the average labelled strength 
as 96.4% and 98.8% respectively. Though the accuracy of the two 
methods compares favourably, the official method is more precise 
than the nmr method.
The C(CH^)^ signal could not be used for the analysis because of 
signal overlap with excipients.
3.3.7 'TANDERIL* (Geigy)
'Tanderil' is a tablet preparation containing oxyphenbutazone 
(3:2) (100 mg per tablet).
C H f C H a j C H s
[3; 2)
The nmr assay of tanderil involves the use of 3-acetobenzthiophene 
and the iCH^)^-CH^ resonance signals at 60.8 to 2.2 ppm (figure 3:4, 
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153The official assay method for oxyphenbutazone tablets 
utilises an acid-base titration method. The results obtained using 
this method are given in table 3:22, page 240. An average of 97.3% of 
the lablled strength and a variation of 1.32% were obtained by the nmr 
method. The official method had 98.5% as the % labelled strength 
with 0.72% variation. With regard to accuracy, the methods are equally 
good. In terms of sample size, the nmr has the advantage over the 
official method. The official method requires about 500 mg of oxyphen­
butazone for the analysis, whereas the nmr method requires less than 
90 mg. The nmr method is more rapid, though less precise, than the 
official method.
3.3.8 'INDOCID' CAPSULES (M.S.D.)
'Indocid' capsules contain-indomethacin (3:3)  ̂25 mg per capsul^
Cl
\  CH.COOH
The nmr assay of 'Indocid' involves the use of vanillin as:: an 
internal standard (see table 3:1, page 201) and the C-CH^ signal of 
the indomethacin at 62.38 ppm as the sample analytical peak. The 
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A UV method is the official assay method^^^ for indomethacin
capsules. This involves the measurement of the extinction of the
sample in methanol (buffered with a solution of standard^. pH 7.2)
1%at 318 nm. E, = 193 at 318 nm . The results obtained for1cm
this method are given in table 3:24, page 243 .
The nmr method gave a higher % labelled strength (104.6%) than 
the official method (100.9.). Moreover, the nmr method was less 
precise (coeff. var. 2.64%) than the official method (coeff. var. 
0.72%) .
3.3.9 'BUTAZOLIDINE ALKA '
Butazolidine Alka is a tablet preparation containing the following 
active ingredients:
Dried alum, hydrox. gel 100 mg
Magnesium trisilicate 150 mg
Phenylbutazone 100 mg
The phenylbutazone (3:4) content has been determined using nmr and
o
(3:4)
3-acetobenzthiophene as internal standard. The signals from the nine 
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peak (see table 3:33, page 254). The results are given in table 
3:25, page 244.
The U.S.P.^^^ employs a UV method for assay of phenylbutazone
tablets by measuring the extinction of the sample in O.IN NaOH at
264 nm. The method, however, uses an acid-base titration
method. The B.P. method was followed for comparison with the nmr
method. The results are given in table 3:26 (page 245).
The results for the two methods compare favourably with each 
other, both in accuracy and precision. However, the nmr method has 
the advantage of being more rapid and also requiring less material for 
the analysis.
3.3.10 'NAPROSYN'
Naprosyn is a tablet preparation containing Naproxen 250mg.
With 3-acetobenzthiophene as the internal standard and the OCH^ 
and CH signals of naproxen as the sample analytical peaks, the nmr 
assay of 'Naprosyn' gave an average of 95.4% labelled strength with 
a variation of 1.91%. The results are given in table 3:27, page 247 . 
The average % labelled strength obtained by a UV method (page 285 ) 
for 'Naprosyn' was 100.2% with a variation of 0.51%. The results
for the Û 7 method are given in table 3:23 (page 248) .
3.3.11 'BENORAL' TABLETS AND SUSPENSION
'Benoral' (Winthrop) preparations contain benorylate (2:33) (see 
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the suspension contains 4 g benorylate in 10 ml.
'Benoral' tablets and suspension have been assayed using nmr and 
employing maleic acid as the internal standard. The signals for 
the two acetyl groups (table 3:33, page 254) were used for the analysis 
The results are given in tables 3:29, page 250 and 3:30, page 251.
UV assay procedures for the tablets (see section 3.6.2.8, page 
286) and suspension (see section 3.6.2.9, page 286) were also carried 
out for comparison with the nmr method. The results are given in 
tables 3:31 and 3:32, pages 252 and 253.
Both the nmr and UV assay results for the 'Benoral' tablets were 
close. However, the coefficient of variation was higher for the nmr 
method (4.78%) than for the UV method (0.77%).
The nmr method for 'Benoral' suspension gave very high results 
compared with those of the UV method and the labelled strength. This 
might have been due to an irrelevant peak coming under the sample 



















Ü 5P O'0) c
A  <U Id p 
p  p  cn
I>1 no
p 0)


















P  p G Id -Xp noS Gp  Id






1— i CO CO CO A Ip (Ti P CN
0^ CO CO 6 CO CO m ID O CO
r4 p CN p O CN p P O P
f-4 Ip P p P P P P P P
(Si P P CO CN P CN CO r-
p Eh m m CO m P O in on r-'
Id H
P Tf CO CO CO CO TT p CO CO
0) "b
p
(Si ma OCN mP iTion CNo 8 pp OCN IDcon O
> H< CN CO CO CN CO CO CO cn CN CO






o <T>CN ID OP
dP00
P P ID on on CN r' O m on 'nr
ID r- CN CO CO* m CN on CO p TTO O on .non o on O O on on O
P P p P P P
O CN m CO on m O ID O P
2 P
TT O in CN CN CO CN on CO CN < d)
CN CN CN O P P CN p O P W 0
P P P P P p p P P P 2 U




6 'T3o O in in O ID m CN o o (Uon CN P on O on O r4 on O P
P 1— 1 P 1-4 r4 p



















1-5P tT> (U C 






C P  
fd A 
P  A  O 0
• Q) A  A  
2  (d








eu V  ■P U G G CPP t eGP  G 









co 'vT CN VD ro ro en CN vD OP O p O P P P O O O P LD1—i P p P p P P 1—1 P P P
CN rH vD O IT) co en P m P CN
en LD CD co CD m en en uo p CD




G eu e0 A üP G
en P LD 00 CN o r- o ro CD p •'d'S en CN ro ro ro CN ro TT •<=r
G ft > M
0 en < ro ro ro ro ro ro ro ro ro roP G
en en
G G
eu A 0ft 0 A p
en 0 en CN CN CN TT ro ro r~ en CO O
G G en
en P eu J TT ro ro CN en en en en CD CN
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'Equagesic' tablets contain the following active ingredients per 
tablet :







C H j O C O N H a  
CH]CH 2CH 2 — C~~ CHj
C H j O C O N H a
(3:6)
COO 2";
C H 2C O O '
ICOHCOOH
ICHjCOOH
The Ethopheptazine citrate (3:5), Meprobamate (3:6) and Aspirin 
content of 'Equagesic' tablets have been determined successfully util­
ising their combined solubilities in acetone (d_) and DMSO(d^), and6 6
using pure meprobamate as the internal standard for the meprobamate 
and aspirin content.
The determination of the ethoheptazine citrate, meprobamate and 
aspirin content together by the use of nmr is not feasible due to 
overlap of resonance peaks. Meprobamate and aspirin are readily
soluble in acetone (d^), whereas ethoheptazine citrate is insoluble.
- 256 -
Extraction of the meprobamate and aspirin with acetone (d ) leaves6
ethoheptazine citrate, CaCO^ and other excipients behind. When the 
residue is treated with DMSO(d^), the ethohephazine citrate is 
dissolved. Maleic acid was used as an internal standard for the 
ethoheptazine citrate. For the meprobamate and aspirin, the 2{CH^0) 
signal at 53.8 ppm belonging to the meprobamate and the COCH^ signal 
at 52.2 ppm for the aspirin were employed for the analysis. Two 
simultaneous equations were used for the calculations of the aspirin 
and meprobamate contents. The method of calculation is given below 
and the experimental details are given in section 3.6.3.1, page 286.
Method of calculation
Meprobamate and aspirin determination 
Explanation of symbols used:
Int. A - Integral of aspirin COCH^ signal in the 1st sample.
Int. A' - Integral of aspirin COCH^ in the 2nd sample.
Int. B - Integral for the 2{CH^C)) signal of meprobamate in the
1st sample
Int. Bs - Total integral for the standard meprobamate and the
meprobamate content of the tablets in the 2nd sample. 
E^ - Equivalent wt. of aspirin = 60.05
Eg - Equivalent wt. of meprobamate = 54.6
- Wt. of aspirin in the sample.
Wg - Wt. of meprobamate in the sample.
Wgg - Wt. of standard meprobamate added to the sample.
Int. A E X  W
Ratio   =   ... (1)
Int. B E, X  WA B
-257-




Int. A X E X W __________ A B
Int. B X E„
KW (3:
where K =
Int. A X E.
Int. B X E,
From equation (2) W.
Int. A' X E^ X (W_+W_ ) ___________ A_____ B Bs
Eg X Int. (Bs)
K' (W„ + W ) B Bs
K'Wb + K'Wgg
K'Wg + S (4)
where K' =
Int. A'xE.
Int.B xE„ s B
and S = K ' W,BS
KWB K'W + S B
KW„ - K'W„ B B
Wg(K - K')
WB' K - K ’
(5)
W^ can be obtained by substituting Wg in either (4) or (3)
-258-
For the ethoheptazine citrate determination the aromatic signals 
were employed as the analytical peaks. The results for the aspirin 
and meprobamate are given in table 3:34, page 259 and those for etho­
heptazine citrate are given in table 3:35, page 260.
The official assay methods for determining the aspirin^^^ mepro- 
bamate^^^ and ethoheptazinecontents were also performed. For the 
aspirin content, the method involves extraction procedures followed by 
conversion into salicylic acid. The latter is then treated with ex­
cess O.IN bromine (50 ml) and back titrated with O.IN sodium thiosulphate 
after addition of potassium iodide solution. The results are given 
in table 3:38, page 263. The results for the official method (av. 
labelled strength, 98.0%) compare well with those obtained by the nmr 
method (97.4%).
The official method for meprobamate content is based on conversion 
of the amide into ammonia. The ammonia liberated is distilled into 
O.IN HgSO^ (50 ml) and the excess H^SO^ titrated with O.IN NaOH. The 
results are given in table 3:36, page 261. The average % labelled 
strength obtained (101.0) agrees with that obtained by the nmr method 
(102.6%).
172The N.F. method was followed for the ethoheptazine citrate 
content. The method involves conversion of the salt (ethoheptazine 
citrate) to the base (ethoheptazine) and extraction of the latter into 
CCl^. The base is determined by a non-aqueous titration involving 
the use of 0.05N perchloric acid in glacial acetic acid. The results 
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The nmr method is faster than the official method. For a single 
determination, the time involved for the determination of aspirin, 
meprobamate and ethoheptazine citrate by the nmr method was 30 - 
40 minutes. The time for the official methods was 3 - 4  hours. 
However, the offical methods were more precise than the nmr method.
3.4.2 'CODIS'
'Codis' is a tablet preparation containing aspirin (500 mg) 
and codeine phosphate (8 mg) as the active ingredients.
The aspirin and codeine phosphate content of 'Codis' have been 
determined by nmr assay using p-t-butylbenzoic acid as the internal 
standard. In view of the low codeine phosphate content, analar 
codeine phosphate was added to the sample to increase the sensitivity. 
The results are given in table 3:39, page 265.
The official assay method^^^ was used to determine the aspirin and 
codeine phosphate content. The method for codeine phosphate is 
an acid-base titration. The codeine base was generated from the 
phosphate proton salt and treated with standard sulphuric acid.
The excess sulphuric acid was determined by titrating with sodium
hydroxide. The results for both determinations (aspirin and
codeine phosphate) are given in tables 3:40 and 3:41, pages 267 and 268
The results obtained by both methods (nmr and official) agreed 
except that the coefficient of variation for the nmr method was 
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'Cafadoi' is a tablet preparation containing paracetamol (500 
mg) and caffeine citrate (30 mg) as the active ingredients.
An nmr method of determination of paracetamol and caffeine 
citrate has been carried out using p-t-butyl benzoic acid as the 
internal standard, and pure caffeine citrate to raise the nmr sig­
nal sensitivity of the caffeine citrate content in the tablet.
As with 'Codis' (section 3.4.2, page 264 ) the caffeine citrate 
content of 'Cafadoi' is low compared in relation to the paracetamol, 
Addition of analar caffeine citrate is necessary. The results are 
given in table 3:42, page 270.
Despite the low content of caffeine citrate in a tablet, the 
result obtained is quite satisfactory. It appears that for low 
content ingredients, the use of the pure drug to increase the 
sensitivity can give satisfactory results.
The paracetamol content - complies with the official requirements 
(95.0 - 105.0%).
3.4.4 'PARAHYPON'
'Parahypon' is a tablet preparation containing the following 
active ingredients per tablet:
Paracetamol 500 mg
Caffeine 10 mg
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The active ingredients of 'Parahypon' have been determined 
using p-t-butylbenzoic acid as the internal standard. In view of 
the low caffeine and codeine phosphate contents, analar caffeine 
and analar codeine phosphate were added to raise the sensitivity 
level of the two substances in the tablet. The results obtained 
from this analysis are given in table 3:43, page 274 . The nmr 
spectrum for the assay of 'Parahypon' is given in figure 3:5, page 
272.
The results for the paracetamol and caffeine were satisfactory 
but for codeine phosphate unsatisfactory results were obtained. The 
average % labelled strength obtained for paracetamol, caffeine and 
codeine phosphate were 96.6, 94.2 and -1.6 respectively. The poor 
results obtained for codeine phosphate indicates that there is a 
limit to the quantity of codeine phosphate per tablet suitable for 
nmr analysis, even when analar codeine phosphate is added.
3.4.5 'FRANOL' EXPECTORANT
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An attempt to use nmr to assay this preparation failed. The 
phenobarbitone and the ephedrine contents are too low to be assayed 
accurately by nmr, but the theophylline monohydrate (3:7) and 
the guaiphenesin (3:8) contents are present in sufficient quantity 
for nmr analysis. The nmr spectrum of the chloroform extract of 
the preparation (figure 3:6, page 277) revealed the presence of 
additional resonance from excipients, which precluded quantification 
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3.5 CONCLUSION
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NMR is a technique suitable for quantitative analysis of 
pharmaceuticals. The nmr method reported here has the advantage 
over most existing methods of speed, specificity, sample size and 
simplicity. NMR affords accurate analysis comparable with the 
existing methods, although the precision is not so great.
The suitability of the nmr method for quantitative pharmaceu­
tical analysis depends on the method of measurement of the analytical 




NMR spectra were recorded on a Perkin Elmer R12B instrument
o ooperating at 60 MHz, with a probe temperature of 37 ± 1 C. Except
where the solvent was CDCl^, D.S.S. was used as internal reference 
standard. With CDCl^ as solvent, TMS was the internal reference 
standard.
UV absorbances were measured on a Perkin Elmer 124 instrument.
Chemicals used were obtained from the following sources:
Analar maleic acid was purchased from the British Drug House. 
All other internal standards mentioned in table 3:1A (page 201) 
were purchased from Aldrich Chemical Co. Ltd.
Gentamicin sulphate samples were supplied by the Nicholars 
Laboratories Ltd.
Ethoheptazine citrate and meprobamate were supplied by John 
Wyeth & Brother Ltd., Maidenhead.
Acetylsalicylic acid was purchased from Evans Chemical Co., 
Bristol.
All the tablets, capsules and suspensions were purchased from 
M.I. and J.T.R. Owen Chemists, Bristol.
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3.6.1 Gentamicin Analysis
3.6.1.1 Gentamicin sulphate assay
3.6.1.1.1 Gentamicin sulphate powder
Gentamicin sulphate (Ca 0.09 g) and maleic acid (Ca 0.05 g) 
were dissolved in D^O (0.5 ml). The nmr spectrum was recorded and 
the appropriate signals integrated several times.
3.6.1.1.2 Gentamicin injection
2 ml of each ampoule were pipetted into small beakers and left 
in an oven at a temperature of 40°C and a pressure below 5 mm Hg to 
remove solvent. The residue, together with maleic acid (Ca 0.04 g), 
was then dissolved in D^O (0.5 ml). The nmr spectrum was recorded 
and the appropriate signals integrated.
3.6.1.2 Chromatographic separation of the major components of the 
gentamicin complex
164The method of Wagman, Marquez and Weinstein was followed.
Adsorbent - Cellulose (Whatman cellulose powder std.
grade
Mobile phase - Lower layer of a mixture of chloroform,
methanol and 17% ammonia (2:1:1).
Length of column - 40 cm.
Width - 2 cm.
Rate of flow - 20 ml./15 min.
Sample - Gentamicin sulphate powder (4.0 g) Batch No.
GMC 4-X-6007.
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The Gentamicin sulphate was mixed with cellulose (20 g). The 
mixture was placed on top of the packed column and moistened with 
a few ml. of the upper layer of the chloroform, methanol and 17% 
ammonia mixture.
Fractions were collected at 10 -15 min intervals.
Component Fraction No. Weight (mg)
=1 3-6 . 198.6
^2 10-17 103.9
^1$ 30-39 59.7
164The gentamicins were detected by descending paper chromatography
3.6.2 Pharmaceutical preparations containing one active ingredient
3.6.2.1 NMR assay of tablets
The average weight of a tablet was obtained from 20 tablets.
The tablets were powdered and a known weight of the powder suspended 
in the appropriate solvent together with the internal standard (see 
table 3:33, page 254). The mixture was allowed to stand for at 
least 5 mins. with occasional shaking to ensure complete dissolution. 
The mixture was either centrifuged or filtered through a cotton wool 
plug saturated with the solvent. The nmr spectrum of the clear super­
natant layer or the filtrate was recorded and the analytical regions 
(see tables 3:1, page 201 and 3:33), integrated at least five times.
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3.6.2.2 NMR Assay of suspensions
(see tables 3:11, page 223 and 3:30, page 251 for details of 
the quantities of the suspension and internal standard used).
A sufficient quantity of the suspension was mixed with the in­
ternal standard and the solvent (table 3:33). The mixture was 
stirred for about 10 minutes, then centrifuged or filtered through 
a cotton wool plug already saturated with the solvent. The nmr 
spectrum of the clear layer or filtrate was recorded and the analy­
tical regions integrated several times.
3.6.2.3 NMR assay of capsules
(see tables 3:16, page 229, 3:23, page 242 and 3:33, page 254 
for the quantities of samples, internal standards and solvents 
employed).
The contents of ten capsules were weighed together and a known 
weight equivalent to a sufficient quantity of the active ingredient 
suspended in the appropriate solvent, together with the internal 
standard. The mixture was either filtered or centrifuged after 
occasional shaking for 5 minutes. The nmr spectrum of the filtrate 
or the supernatant layer was recorded and the analytical peaks 
integrated.
3.6.2.4 UV assay of 'Orudis* capsules
The contents of ten capsules were weighed. The weight of the 
powder equivalent to 50 mg of ketoprofen was suspended in methanol 
(Ca 50 ml). It was then filtered into a 200 ml volumetric flask 
and the volume made up with methanol. 5 ml. of the solution was
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diiuted to 100 mis with methanol. The absorbance in a 1 cm layer 
of the resulting solution at 253 nm was recorded. The absorbance 
(0.89) at 253 nm of a standard ketoprofen solution (0.00131%, w/v) 
in methanol was employed for the calculation.
3.6.2.5 UV assay of 'Brufen* suspension
A weight of the suspension equivalent to about 20 mg of ibuprofen 
(table 3:13, page 225) was mixed with methanol (20 ml) and stirred 
for 10 minutes. The mixture was then filtered. The filtrate was 
diluted with methanol (to 100 ml) and 5 ml of the resulting solution 
further diluted with methanol (to 100 ml). The extinction of the 
final solution in 1 cm layer was measured at 222 nm. The extinction 
(0.430) of a standard ibuprofen solution (0.00103%, w/v) in methanol 
at 222 nm was used for the calculation.
3.6.2.6 UV assay of *Brufen' tablets
A weight of powdered tablet equivalent to about 27 mg of ibuprofen 
(table 3:12, page 224) was suspended in methanol (30 ml) and stirred 
for 10 minutes. The mixture was then filtered. The filtrate was 
diluted with methanol (to 100 ml) and 5 ml of the resulting solution 
further diluted with methanol (to 100 ml). The extinction of the 
final solution in 1 cm layer was measured at 222 nm. The extinction 
(0.430) of a standard ibuprofen solution (0.00103%, w/v) in methanol 
at 222 nm was used for the calculation.
3.6.2.7 UV assay of 'Naprosyn' tablets
A weight of powdered tablet equivalent to about 20 mg of 
naproxen (table 3:28, page 248) was suspended in methanol (30 ml).
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stirred for 10 minutes and then filtered. The filtrate was diluted 
with methanol (to 100 ml). 5 ml of the resulting solution was 
further diluted with methanol (to 50 ml). The extinction of the 
final solution in a 1 cm layer was measured at 273 nm. The ab­
sorbance (0.532) of a standard naproxen solution (0.00205%, w/v) in 
methanol at 273 nm was employed for the calculation.
3.6.2.8 UV assay of 'Benoral' tablets
About 22 mg of powdered tablet (see table 3:31, page 252) was
dissolved in hot methanol (20 ml) and then diluted with methanol
(to 100 ml). 5 ml of the solution was further diluted with methanol
(to 200ml). The absorbance of the resulting solution at 240 nm in a
1 cm layer was recorded- The absorbance (0.410) of a standard
-4benorylate solution (5.175 x 10 %, w/v) in methanol at 240 nm was 
used for the calculation,
3.6.2.9 UV assay of 'Benoral' suspension
A quantity of the suspension equivalent to 20 mg of benorylate
(table 3:32, page 253) was mixed with hot methanol (30 ml) and stirred
for 5 minutes. The mixture was filtered and diluted with methanol
(to 100 ml). 5 ml of the solution was further diluted with methanol
(to 200 ml). The absorbance of the resulting solution at 240 nm in
a 1 cm layer was recorded. The absorbance (0.410) of a standard
-4benorylate solution (5.175 x 10 %, w/v) in methanol at 240 nm was 
used for the calculation.
3.6.3 Assay of formulations containing more than one active ingredient
3.6.3.1 NMR assay of 'Equagesic* tablets
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3.6.3.1.1 Meprobamate and aspirin determination
20 tablets were weighed and powdered. Two equal weights of 
the powdered tablets (Ca 250 mg each; table 3:34, page 259) were 
taken. Pure meprobamate (Ca 83 mg) was added to one of them.
The two samples were suspended separately in acetone(d^; 2 ml), 
filtered/centrifuged, and the clear solution used for the. analysis. 
(The residue was reserved for ethoheptazine citrate determination). 
The nmr spectra of the two solutions were recorded and the region 
between 62.0 - 64.5 ppm integrated several times.
3.6.3.1.2 Ethoheptazine citrate determination
Maleic acid (Ca 40 mg; table 3:35, page 260) was added to the 
residue from the meprobamate/aspirin determination (section 3.4.6.1.1) 
and suspended in DMSO(d^; 0.7 ml). The suspension was stirred for 
about 5 minutes and filtered through a cotton wool plug saturated 
with DMSO(d^). The nmr spectrum of the filtrate was recorded and 
the region between 66.0 and 68.0 ppm integrated several times.
3.6.3.2 NMR assay of 'Codis', 'Cafadol' and 'Parahypon'
(see tables 3:39, page 265 , 3:42, page 270and 3:43, page 274 
for the weights of the internal standard and the powdered samples; 
and table 3:44, page 279 for the volume of solvent used.).
The average weight of twenty tablets was found and the tablets 
powdered. A known weight of the powdered sample together with the 
internal standard and a pure compound of caffeine, caffeine Citrate 
or codeine phosphate, where appropriate was suspended in DMSO(d^).
The mixture was either centrifuged or filtered. The nmr spectrum
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of the clear solution obtained was recorded and the appropriate 
regions (see table 3:44, page 274) integrated at least five times
PART 4
4. KINETIC STUDIES ON 'BENORAL' SUSPENSION
4.1 INTRODUCTION
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To obtain the shelf life of a pharmaceutical preparation, 
the formulation must be stored under room temperature conditions 
and periodically assayed until its potency has fallen to 90% or 
less. This is obviously tedious, uneconomical and time consuming- 
Accelerated stability studies at higher temperatures have proved
useful in predicting in a very short time the shelf life of pharma-
H ^ 185-191 ceutical products
The prediction of shelf life by accelerated tests is based on 
the quantitative application of fundamental physicochemical prin­
ciples based on the Arrhenius equation:-
k = A -Ea/RT ...(4:1)e
where 'k ' is the specific rate of degradation of the active 
ingredient;
-1 -1'R' is the gas constant (1.987 calories degree mole );
'A' is a constant which can be entropy of the reaction 
and/or collision factors;
'Ea' is the heat of activation (activation energy) 
and 'T' is the absolute temperature.
The logarithmic form of equation (4:1)
log k = - (Ea/2.303R)/ (1/T) + constant ...(4:2)
shows that a plot of log. k against the reciprocal of the absolute 




The k values for the decomposition of a drug at different 
elevated temperatures are obtained by plotting some function of 
concentration against time on an appropriate graph paper (linear, 
semilog or log-log) depending on the order of the reaction.
For a pseudo-zero order reaction,
dy/dt = -K ...(4:3)o
i.e. y = y - k t ...(4:4)o o
where y^ and y are the initial and final concentrations at zero time 
and time t respectively. Plots frcm such a relationship are linear 
with a gradient equal to
-k
For a pseudo-first order reaction,
log y = log y - ( k ) t ...((4:5)
° 2.303
In this case the logarithmic form of the concentration is plotted 
against time to obtain a linear plot. The slope is given by
-k/2.303
from which 'k' can be calculated^^^.
In accelerated storage testing, a function of the concentration 
is plotted against time at various elevated temperatures. The 
slopes (and hence k) for the linear plots for the various temperatures 
are then converted to the logarithmic form and plotted against the 
reciprocal of the absolute temperature. The linear plot obtained 
is extrapolated to the room temperature to obtain the rate constant. 
This procedure was adopted for the kinetic studies on ’Benoral' 
suspension.
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'Benoral' is the proprietary name for pharmaceutical preparations 
containing benorylate (4-acetamidiophenyl 2-acetoxybenzoate; 2:33)
O C O C H 3
( 2:33)
Benorylate is an anti-inflammatory analgesic and antipyretic 
used for.the treatment of rheumatoid arthritis, osteoarthritis and 
other painful musculoskeletal conditions. It may also be used to 
relieve mild to moderate pain due to many other causes, and as an
antipyretic in febrile conditions. 'Benoral' may only be admini-
77 183stered orally
The pharmacological actions of benorylate are closely related
to those exhibited by aspirin, but it has the advantage of much
184reduced gastric irritation . The drug is degraded in vivo to 
aspirin (4:1) and paracetamol (2:32).
4.2 DISCUSSION




Possible Degradation Products of Benoryiate
Ô C O C H 3 / = \  
(2:33)
OH
NH COCKC O O
CH3  COOH






'Benoral' suspension contains 40% w/v benoryiate. The stability
study on this suspension was initiated since it was considered that
the presence of two phenolic ester groups in the molecule might
render it particularly susceptible to hydrolysis. Hydrolysis products
of benoryiate include paracetamol (2:32), aspirin (4:1), phenetsal
(4:2), and salicylic acid (4:3) see scheme 4:1 . The presence of
184aspirin in the suspension would lead to gastric irritation
A consideration of the structures and properties of the possible 
degradation products of benoryiate (scheme 4:1), suggested that nmr 
would be an appropriate method for the stability studies, using the 
two resonance signals at 62.25 ppm and 62.10 ppm associated with the 
O-COCH^ and NHCOCH^ groups respectively. This would be possible only 
if the degradation product was mainly phenetsal and associated acetic 
acid. Since the acetic acid CH^ resonance (61.99 ppm) is well 
separated from the signals employed for analytical purposes, and the 
NHCOCH^ resonance peak - belonging to the phenetsal (62.05 ppm) 
almost coincides with that of benoryiate (62.10 ppm), the ratio between 
the two resonance peaks (62.10/62.25) would be a measure of the amount 
of phenetsal present. On the other hand, if the degradation product 
consisted of paracetamol and aspirin in addition to phenetsal, the 
two analytical peaks (62.10 and 62.25) could not be used. However, 
the presence of paracetamol would reveal extra peaks in the region 
66.6 to 66.85 ppm due to two of the aromatic protons which could be 
used for the analysis. Unfortunately application of nmr to the 
problem was not successful because the amount of the degradation 
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The concentration of phenetsal produced at 40°C for three days was 
0.15% (see tables 4:1 and 4:2, page 3o?) which is outside the range 
detectable by the instrument.
The failure of the nmr method made it necessary to find a more 
sensitive method. A consideration of the nature of the parent com­
pound and the possible degradation products ruled out the use of 
ultraviolet (UV) or infrared (IR) spectroscopy. Since most of the 
degradation products are phenolic, a colorimetric method was employed 
for the estimation of the phenolic degradation products.
4.2.1 Colorimetric method
The reaction of a 4-aminophenazone derivative (4:4) with 
192phenols was employed for the stability study (scheme 4:2). In 
the presence of potassium ferricyanide in an alkaline medium, (4:4) 
reacts with phenols to give a coloured compound which is not stable 
in aqueous solution but which is stable in chloroform. The reaction 
is only given by phenols with the para- position free. Thus in a 
study of benoryiate hydrolysis only phenetsal and salicylic acid 
give a coloured derivative with reagent (4:4) The colour given by 
both phenetsal and salicylic acid has an absorption maximum at 480 nm,
Aliquots of ’Benoral* suspension were heated at different temp­
eratures and then analysed at time intervals (see page 314 for 
experimental details). The experiment was repeated using a freshly 
prepared suspension of benoryiate in water. Also portions of the 
'Benoral' suspension were buffered to different pH values and 





























experiment was to find the effect of pH on the stability of the 
suspension. Phenetsal was synthesised from salicylic acid and para­
cetamol (scheme 4:3)and used for calibration purposes. The results 
are presented in tables 4:1 to 4:,7 (pages 307-312) and in figures
4:1 to 4:7 (pages 295, 301 and 303-305).
The results in table 4:2 and 4:5 (pages 308-311) show only a 
short linear relationship between the time and absorbance for all the 
various temperatures except for 30°C. A linear relationship over 
the entire period of the experiment was anticipated but not observed. 
Instead, the absorbance increased linearly with time over a short 
period and then decreased. These curious results initiated an 
investigation of the degradation pattern of benoryiate. It seems 
that, initially the benoryiate degraded to form phenetsal and acetic 
acid, the former yielding a colour with the 4-aminophenazone (4:4). 
With time, the phenetsal yielded salicylic acid and paracetamol, or 
the benoryiate degraded to acetylsalicylic acid and paracetamol, or 
perhaps both occurred. The presence of paracetamol changed the 
absorption maximum from 480 nm to a lower wavelength, depending on 
the concentration of paracetamol present. Figure 4:1 (page 295) 
shows the absorption curves obtained for the 'Benoral' suspension 
buffered to pH 8 and maintained at 35°C. From figure 4:1, it is 
seen that there was a gradual, or essentially a linear, increase of 
absorbance at 480 nm with time up to 24 hours. At 72 hours, the 
absorbance at 480 nm fell below that at 6 hours. To prove whether 
this unusual absorption curve was actually due to the presence of 
paracetamol, 2 different weights of^paracetamol were added to two,
6 ml aliquots of the 'Benoral' suspension. The absorption curves
-297-












































obtained after treatment with the 4-aminophenazone (4:4) are given 
in figure 4:2, page 298. For comparison, 6 ml of the same 'Benoral' 
suspension was treated in the same way in the absence of paracetamol. 
The absorption curve recorded was similar to figure 4:1, O hour 
(page 295^.^ . Paracetamol itself was treated with the 4-aminophenazone 
reagent and the absorption curve of the resulting solution recorded
(figure 4:3, page 300 ) . There was no absorption maximum in the
visible region. All these results indicated the presence of para­
cetamol as part of the degradation process. The shape of the ab­
sorption curve of phenetsal itself after treatment with the 4-amino­
phenazone (figure 4:3, page 300 ) is similar to that of the 'Benoral' 
suspension at room temperature. This confirms that the initial 
degradation product of benoryiate is phenetsal.
Further evidence for the presence of paracetamol was obtained 
by treatment of the 'Benoral' suspension, at 50°C, with ferric 
chloride solution at 6 hour intervals. Only those suspensions 
which gave absorption curves similar to figure 4:2, page 293 , 
gave a violet to blue colour. This was known after filtering the 
suspension through a cotton wool plug - the cotton wool became violet 
to blue . The experiments proved that paracetamol was not the 
initial degradation product, but was produced after the production 
of phenetsal.
4.2.2 Effect of pH on stability of 'Benoral' suspension
The stability of the 'Benoral' suspension at different pH 
values at a constant temperature of 35°C is shown in figure 4:4, 
page 301. As seen from the table of results (table 4:5, page 211) 
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pH values over the entire period of the experiments due to the 
production of paracetamol. However, at or before 6 hours duration 
of the experiment, paracetamol had not been produced and the results 
up to 6 hours can therefore be used to relate the stability studies 
at different pH values (pH 4 - 10). It is evident from figure 4:4 
that in the pH range 5 to 7.4 stability is at a maximum. Outside 
this range, the benoryiate undergoes rapid hydrolysis. 'Benoral' 
suspension is formulated at pH of about 5.4 .
Table 4:6 shows the results of the stability of 'Benoral' 
suspension at pH 10.3. The results obtained could not be incorporated 
into figure 4:4 because the suspension used was from a different 
batch. However, the results give an indication of the instability 
of 'Benoral' suspension at high pH values.
4.2.3 Calculations of the shelf life at 25°C and 90% potency (t^^)
To predict the length of time required for the 'Benoral' sus­
pension to reach 90% potency at room temperature (25°C), the rate 
constant (k) at 25 C had to be obtained from the log k/l/T plot 
(figure 4:6, page 304). The 'k ' value obtained from the graph was 
the absorbance increase per hour due to the production of phenetsal.
The amount of phenetsal produced per hour was obtained from the 
calibration curve (figure 4:7, page 305). The value obtained was 













































































Once the rate constant (k) for the benoryiate degradation per hour 
at 25°C was known, the length of time (t^^) required for the 'Benoral' 
suspension to fall to 90% potency was obtained by application of 
the zero order reaction rate:
A = A - kt t o
where 'A^' and 'A^' are the initial (100%) and final (90%) potencies 
of the drug.
4.2.4 Prediction of the shelf life at 25°C (t^^)
The 'Benoral' suspension gave an average shelf life at 25°C of 
28 months (basing the calculation on t^^) Table 4:7, page 313.
A more striking result obtained was the shelf life for the freshly 
prepared benoryiate suspension in water. A shelf life of 4.9 years 
was obtained.
From figure 4:6, page 304, it is seen that a linear relationship
between log k and 1/T was obtained for temperatures up to 60^0. There
was no linear relationship at 70°C. This is in agreement with 
182Grimshaw's report on the accelerated stability testing of
pharmaceutical products. In his report Grimshaw pointed out that
60°C is the highest temperature suitable for accelerated stability
testing for suspensions. For coated tablets and dry tablets, the
o ohighest temperatures are 45 C and 80 C respectively.
In conclusion, it is probable that the linear relationships 
obtained for the absorbance versus time (figure 4:5, page 303) and 
log k versus 1/T (figure 4:6, page 304) graphs are an indication of 
the suitability of the method for the prediction of the shelf life 
of 'Benoral' suspension.
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Table 4:1 Results for the calibration curve of phenetsal
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4.3 EXPERIMENTAL
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Colorimetric determinations were carried out on a Sp 600 
spectrophotometer series 2 and a Perkin Elmer 124 instrument.
The pH was determined using a PHM 64 Research pH meter supplied 
by Howe and Co.
Materials: Pure benoryiate was supplied by Winthrop Laboratories,
'Benoral' suspension (3 bottles, each containing 300 ml) was 
purchased.
4.3.1 Synthesis of Phenetsal (p-Acetamidophenyl salicylate)
Salicylic acid (20 g) was treated with thionyl chloride (10.5
ml) in 1,4-dioxan (50 ml) and the mixture refluxed at 100°C for
five hours maintaining an anhydrous environment with a silica gel
guard tube. The excess thionyl chloride and 1,4-dioxan were removed
in vacuo. The residue was dissolved in pyridine and added drop-
wise to paracetamol (21.9 g) in pyridine (20 ml) and maintained at
room temperature overnight with stirring. The reaction mixture
was poured into cold water (500 ml) and the precipitated solid
filtered and recrystallised twice from ethanol. The phenetsal
(1.5 g; 3.8%) had m.p. 186 - 188°C (lit.^^^ m.p. 187^0).
ô(DMSO(d^): 2.05 (3H, S, -COCH), 6.70 - 7.89 (8H, m, 8 x Ar-H) .5 3
4.3.2 Reagents
The 4-aminophenazone (4:4) solution: 2,3 dimethyl-4-aminophenazone
(0.5 g) was dissolved in water (15 ml) and sufficient water added 
to produce 25 ml. The solution was protected from light .
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Strong ammonia buffer: Ammonium chloride (0.575 g) was dissolved
in strong ammonia (5.7 ml) and diluted with water (to 10 ml).
Dilute ammonia buffer: Strong ammonia buffer (2 ml) was diluted
with water (to 1000 ml).
Potassium ferricyanide solution: Potassium ferricyanide (2 g)
was dissolved in water (16 ml) and sufficient water added to produce
25 ml. The solution was freshly prepared.




Water to 80 mis
r
The pH of the suspension was adjusted to 5.4 using ammonium acetate 
w  153buffer . -
4.3.4 The Kinetic studies
Aliquots (40 ml) of the 'Benoral' suspension and the benorylate 
suspension were maintained at different temperatures in ovens and 
constant temperature water baths. At various time intervals 
aliquots (6 ml) of the suspensions were diluted with dilute ammonia 
buffer (20 ml) and transferred to a separating funnel. The 4- 
aminophenazone solution (1- ml) and potassium ferricyanide solution 
(1 ml) were added to the suspension. The mixture was then shaken 
and the coloured derivative extracted into chloroform. The 
chloroform extract was passed through a cotton wool plug into a
-316-
50 ml volumetric flask and diluted to volume with chloroform.
The extinction at 480 nm was measured using 1 cm cells. The con­
centration of phenetsal produced was obtained from a calibration 
curve of phenetsal at 480 nm (figure 4:7, page 305 and table 4:1, 
page 307 ). The results for the kinetic studies are given in 
tables 4:2 - 4:4, pages 308-310, and in figures 4:5 and 4:6, 
pages 303 and 304 respectively.
4.3.5 The effect of pH on 'Benoral* suspension
Aliquots (40 ml) of 'Benoral' suspension were buffered to 
different pH values using ammonium acetate b u f f e r a n d  strong 
a m m o n i a  buffer. The buffered suspensions and an unbuffered sus­
pension (pH 5.4) were maintained at 35°C and aliquots (6 ml) 
withdrawn at time intervals for analysis (section 4.3.4). The 
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6. APPENDIX




In the region of the minimum (A), suppose the left hand curve 
is f(x), the right hand curve is g(x); when we assume f  < O, 
g' > Of f" > Of g" > Of and f, g such that for all relevant p,
(l-p)f + pg has a minimum.
Suppose the minimum at Z, with minimal value h; the consequence 
of perturbing p to (p+ 6p) is considered.
Write ^(x) for (l-p)f(x) + pg(x). Thus z is governed by ;ç ' (z) = O.
i.e. (l-p)f'(z) + pg'(z) = O
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Thus to find ôz, we use
(l-p-6p)f'(z+ 5z) + (p+ ôp)g'(z+ôz) = O 
i.e. (j)'(z+ 6z) + 6p (g' (z+6z)-f ' (z+6z) ) = 0
And expanding
(z) 6z + 0(6z^) + 6p(g'(z)-f'(z) + 0(6z)) = 0
where ôz = ^ ôp + O(ôp^)
so h+ 6h = (1-p-ôp)f (z+ôz) + (p+ôp)g(z+ôz)
= (j)(z+ôz) + ôp (g (z+ôz)-f (z+ôz)
so ô h = (|)'(z)ôz + (̂J)"(z)ôZ^ + 0(ôz)^ + ôp(g(z)-f(z)
+ (g'(z) - f'(z)) ôz + 0(ôz^))
= {(j)'(z)ôz + (g(z)-f(z)) ôp} + (̂j)"(z)Ôz^
2 3+ (g'(z)-f'(z))ôpôz) + O ( pôz f ôz )
(g(z)-f(z)ôp + {}s(j)’'(z) ^
(j)"(z)
+ (g' ( z ) - f '  (z) ) - <Sp̂  + O(ôp^)
(g(z)-f (z) ) ôp - h (GP^^ + O(ôp^)
Thus ôh is approximately linearly related to ôp, with coefficient 
g(z) - f(z), but the quadratic term does not vanish, and indeed 
the coefficient
2(g'(z)-f'(z)) need not even
4>"(z)
be particularly small; we know g' >0, f  < O.
